Page last updated: 2024-08-25

sofosbuvir and ledipasvir

sofosbuvir has been researched along with ledipasvir in 316 studies

Research

Studies (316)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's248 (78.48)24.3611
2020's68 (21.52)2.80

Authors

AuthorsStudies
Dadej, A; Jelińska, A; Muszalska, I; Sobczak, A; Tomczak, S; Zając, M1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Ding, X; Hyland, RH; Lawitz, E; McHutchison, JG; Membreno, FE; Mo, H; Pang, PS; Poordad, FF; Symonds, WT1
Ding, X; Gane, EJ; Hyland, RH; McHutchison, JG; Pang, PS; Stedman, CA; Subramanian, GM; Svarovskaia, E; Symonds, WT1
An, D; Bernstein, DE; Chojkier, M; Di Bisceglie, AM; Fried, MW; Ghalib, R; Gordon, SC; Herring, R; Hyland, RH; Kowdley, KV; Lawitz, E; McHutchison, JG; Muir, AJ; Pang, PS; Pockros, PJ; Pound, D; Reddy, KR; Rossaro, L; Rustgi, V; Ryan, M; Schiff, E; Shiffman, ML; Subramanian, GM; Svarovskaia, E; Symonds, WT1
Hoofnagle, JH; Sherker, AH1
Afdhal, N; Arora, S; Di Bisceglie, AM; Dvory-Sobol, H; Ghalib, R; Gitlin, N; Gordon, SC; Herring, R; Kwo, P; Lalezari, J; Lawitz, E; McHutchison, JG; Muir, AJ; Nahass, R; Nelson, DR; Pang, PS; Pockros, PJ; Reddy, KR; Schiff, E; Subramanian, GM; Sulkowski, M; Symonds, WT; Yang, JC; Younes, ZH; Zhu, Y1
Afdhal, N; Agarwal, K; Bräu, N; Buggisch, P; Buti, M; Chojkier, M; Ding, X; Foster, GR; Gitlin, N; Jacobson, IM; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Mo, H; Muir, AJ; Pang, PS; Puoti, M; Romero-Gomez, M; Subramanian, GM; Symonds, WT; Yang, JC; Zarski, JP; Zeuzem, S1
Feld, JJ1
Sofia, MJ1
German, P; Mathias, A; Moorehead, L; Pang, P; Vimal, M1
Delaney, W; Dvory-Sobol, H; Lawitz, EJ; Mabery, E; McHutchison, J; Miller, MD; Mo, H; Skurnac, T; Svarovskaia, ES; Voitenleitner, C1
Carroll, J1
Fauci, AS; Kohli, A; Kottilil, S; Marti, MM; Masur, H; McHutchison, JG; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Silk, R; Subramanian, GM; Townsend, K; Zhang, X1
Firpi, RJ; Hilgenfeldt, E1
Cornberg, M; Höner zu Siederdissen, C1
Chan, J; Mohammad, RA; Smith, MA1
Nelson, DR; Peter, J1
Foster, GR1
Abbott, S; Barrett, LL; Bon, D; Chavez, J; Diaz, G; Egerson, D; Fauci, AS; Gross, C; Herrmann, E; Jolley, TA; Kapoor, R; Kleiner, DE; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Marti, MM; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Petersen, T; Polis, MA; Proschan, M; Sidharthan, S; Silk, R; Sims, Z; Sneller, M; Spurlin, E; Subramanian, GM; Symonds, WT; Talwani, R; Teferi, G; Townsend, K; Wood, BJ1
Kumari, R; Nguyen, MH1
Beckerman, R; Jiang, Y; Smith, NJ; Stepanova, M; Younossi, ZM1
Floreani, A1
Chhatwal, J; Dunn, MA; Kanwal, F; Roberts, MS1
Afdhal, N; Henry, L; Hunt, SL; Kowdley, KV; Marcellin, P; Stepanova, M; Younossi, ZM; Zeuzem, S1
Keating, GM1
Borgia, SM; Rowaiye, A1
Betular, J; Enomoto, H; Gao, B; Garrison, K; Genda, T; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, SJ; Korenaga, M; McHutchison, JG; Mizokami, M; Mo, H; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Omata, M; Omote, M; Pang, PS; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O1
Halász, T; Horváth, G; Hunyady, B; Makara, M1
Bourlière, M; Bronowicki, JP; Carrieri, MP; Pol, S; Stepanova, M; Younossi, ZM1
Kmietowicz, Z1
Albert, ML; Casrouge, A; Decalf, J; Duffy, D; Kottilil, S; Masur, H; Meissner, EG1
Gross, C; Kapoor, R; Kohli, A; Kotb, C; Kottilil, S; Lam, B; Masur, H; Nelson, A; Osinusi, A; Pang, PS; Polis, MA; Rustgi, V; Sidharthan, S; Silk, R; Sims, Z; Sugarman, K; Teferi, G1
Baden, RP; Bräu, N; Colson, AE; Cooper, C; Dieterich, D; Dvory-Sobol, H; Gane, E; German, P; Jayaweera, D; Luetkemeyer, A; Marks, K; McHutchison, JG; Morales-Ramirez, JO; Naggie, S; Ni, L; Pang, PS; Ruane, P; Saag, M; Santana-Bagur, J; Sax, PE; Stamm, LM; Stedman, CA; Sulkowski, M; Tebas, P; Towner, WJ; Wong, DK; Workowski, K; Yang, JC1
Brunetto, MR; De Luca, A; Messori, A; Zignego, AL1
Hikita, H; Hiramatsu, N; Kai, Y; Morishita, N; Nakabori, T; Nawa, T; Oze, T; Saito, Y; Sakamori, R; Suemizu, H; Takehara, T; Tanaka, S; Tatsumi, T; Yakushijin, T1
Escheik, C; Estep, M; Gerber, L; Stepanova, M; Weinstein, A; Younossi, ZM1
An, D; Brainard, D; Gane, EJ; Hyland, RH; Pang, PS; Stedman, CA; Svarovskaia, E1
Brainard, DM; Elsheikh, E; Gerber, L; McHutchinson, JG; Nader, F; Stamm, LM; Stepanova, M; Younossi, ZM1
Bronowicki, JP; Hézode, C1
Debes, JD; Ricci, P1
Rino, Y; Yamamoto, N; Yukawa, N1
Feld, JJ; Kottilil, S; O'Brien, TR; Pfeiffer, RM1
Beckerman, R; Brown, A; Buti, M; Fagiuoli, S; Mauss, S; Rosenberg, W; Serfaty, L; Smith, N; Srivastava, A; Stepanova, M; Younossi, Z1
Akoth, E; Chavez, J; Emmanuel, B; Gross, C; Kattakuzhy, S; Kohli, A; Kottilil, S; Lam, B; Masur, H; McLaughlin, M; McManus, M; Mo, H; Nelson, A; Osinusi, A; Polis, MA; Price, A; Shrivastava, S; Sidharthan, S; Silk, R; Sims, Z; Tang, L; Teferi, G; Wilson, E1
Akoth, E; Gross, C; Kattakuzhy, S; Kohli, A; Kottilil, S; Masur, H; McHutchison, JG; McLaughlin, M; Mo, H; Nelson, A; Osinusi, A; Pang, PS; Price, A; Sidharthan, S; Silk, R; Sims, Z; Subramanian, GM; Tang, L; Wilson, EM1
Bryce, CL; Chidi, AP; Fine, MJ; Good, CB; Myaskovsky, L; Rogal, S; Rustgi, VK; Smith, KJ; Tsung, A1
Kohli, A; Kottilil, S; Masur, H; Meissner, EG; Osinusi, A; Remaley, AT; Sampson, M; Sidharthan, S; Tang, L; Townsend, K1
Abbott, S; Akoth, E; Chavez, J; Emmanuel, B; Gross, C; Jolley, TA; Kattakuzhy, S; Kohli, A; Kottilil, S; Masur, H; McLaughlin, M; Meissner, EG; Mo, H; Nelson, A; Osinusi, A; Polis, MA; Price, A; Proschan, M; Seamon, C; Sidharthan, S; Silk, R; Sims, Z; Tang, L; Teferi, G; Wilson, E1
Adhoute, X; Ansaldi, C; Benali, S; Bourlière, M; Castellani, P; Halfon, P; Oules, V; Portal, I1
Chahal, HS; Fox, RK; Kahn, JG; Marseille, EA; Ollendorf, DA; Pearson, SD; Tice, JA1
Butt, AA; Chung, RT; Shaikh, OS; Sherman, KE; Yan, P1
Gish, R; Kohli, A; Manch, R; Nafisi, S; Roy, S1
Chen, W; Chen, Y; Jin, L; Lin, W; Pan, C; Pan, Z; Zheng, Y; Zhou, G1
Gordon, LA; Gross, C; Kohli, A; Kottilil, S; Masur, H; Nelson, A; Osinusi, A; Petersen, T; Polis, MA; Seamon, C; Tang, L; Townsend, K1
Afdhal, NH; Eggleton, E; Knox, SJ; Kowdley, K; Mangia, A; Mizokami, M; Omata, M; Pang, P; Park, SH; Saab, S; Subramanian, M; Zhu, Y1
Asselah, T; Boyer, N; Marcellin, P; Martinot-Peignoux, M; Saadoun, D1
Kelley, C; McPhee, F; Signorovitch, J; Swallow, E; Wygant, G1
Abergel, A; Asselah, T; Jiang, D; Kersey, K; Loustaud-Ratti, V; Metivier, S; Mo, H; Pang, PS; Samuel, D1
Birati, EY; Forde, KA; Goldberg, LR; Padegimas, A1
Alkhouri, N; Anthony, S; Guirguis, J; Hanouneh, IA; Rivas, J; Singh, T1
Cheng, G; Corsa, A; Delaney, W; Doehle, B; Dvory-Sobol, H; Gong, R; Han, B; Lee, YJ; Link, JO; Mo, H; Pagratis, N; Peng, B; Perron, M; Tian, Y; Xu, S; Xu, Y; Yu, M1
Henry, L; Nader, F; Stepanova, M; Younossi, ZM1
Chang, TT; Chen, JJ; Chien, RN; Chu, CJ; Chuang, WL; Gao, B; Garrison, KL; Hsu, YC; Hu, TH; Kao, JH; Knox, SJ; Lo, GH; Mo, H; Pang, PS; Peng, CY; Sheen, IS; Wang, HY; Yang, JC1
Kottilil, S; Polis, MA; Rosenthal, ES1
Andreone, P; Gamal, N1
Araújo, ES; Bourliere, M; Canini, L; Chiche, L; Coquet, E; Cotler, SJ; Dahari, H; Graw, F; Halfon, P; Penaranda, G; Renou, C; Riso, A; Uprichard, SL1
Ferriols-Lisart, R; Guglieri-López, B; Merino-Sanjuán, M; Pérez-Pitarch, A1
Chan, HLY; Choi, MS; Dan, YY; Henry, L; Lee, MH; Stepanova, M; Younossi, ZM; Yu, ML1
Ciesek, S; Costa, R; Klempnauer, J; Lohse, AW; Lüthgehetmann, M; Manns, MP; Mix, H; Nashan, B; Otto, B; Pischke, S; Polywka, S; Proske, V; Sterneck, M; von Hahn, T; Wedemeyer, H1
de Lagarde-Sebastián, M; de Miguel-Campo, B; Domínguez-Domínguez, L; Pulido, F1
Henry, L; Hunt, S; Nader, F; Stepanova, M; Younossi, ZM1
Holle, LM; Jensen, CM1
Johnson, S; Marx, SE; Misurski, D; Parisé, H; Saab, S; Sanchez Gonzalez, Y; Virabhak, S; Wang, A1
Nehra, V; Rizza, SA; Tan, EM; Temesgen, Z1
Alshatti, F; Hull, MW; Moosavi, S; Yoshida, EM1
Ferenci, P; Freissmuth, C; Graziadei, I; Gschwantler, M; Hametner, S; Hofer, H; Karpi, A; Kozbial, K; Laferl, H; Maieron, A; Moser, S; Ramona, AZ; Stauber, RE; Stern, R; Vogel, W; Zoller, HM1
Al Zoairy, R; Beinhardt, S; Ferenci, P; Freissmuth, C; Hofer, H; Kozbial, K; Maieron, A; Schmidt, A; Stättermayer, AF; Stauber, R; Stern, R; Strasser, M; Trauner, M; Watschinger, B; Zoller, H1
Tseng, A; Wong, DK1
Cooper, C; Dieterich, D; Dvory-Sobol, H; Han, L; McHutchison, JG; Naggie, S; Pang, PS; Saag, M; Stamm, LM; Sulkowski, M; Yang, JC1
Rosenthal, P; Smith, SK1
Gschwantler, M; Haltmayer, H; Marchart, K; Moser, S; Schìtz, A1
Chen, GF; Chen, J; Cheng, J; Dou, XG; Du, N; Duan, ZP; Fan, JG; Fu, QC; Han, Y; Hou, JL; Ji, D; Jia, JD; Jia, ZS; Lau, G; Li, B; Li, F; Liu, JL; Lu, LG; Niu, XX; Ren, H; Shang, J; Shao, Q; Wang, C; Wang, GQ; Wang, JP; Wang, XJ; Wang, YD; Wei, L; Wong, A; Wu, V; Xie, Q; Yang, XX; Zhang, WH; Zhang, YX; Zhuang, H1
Henry, L; Hunt, S; Naggie, S; Stepanova, M; Sulkowski, M; Younossi, ZM1
Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA1
Basalious, EB; Bendas, ER; Karim, IA; Rezk, MR1
Gonzalez, YS; Johnson, S; Juday, T; Misurski, D; Parisé, H; Saab, S; Virabhak, S; Wang, A1
Brainard, DM; Dvory-Sobol, H; Gutierrez, JA; Hyland, RH; Lawitz, E; Liu, L; McHutchison, JG; Poordad, F; Wang, J1
Abergel, A; Asselah, T; Jiang, D; Kersey, K; Knox, SJ; Loustaud-Ratti, V; Metivier, S; Pang, PS; Samuel, D; Svarovskaia, E1
Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y1
An, D; Brainard, D; Gane, EJ; Hyland, RH; McHutchison, JG; Svarovskaia, ES2
Aichelburg, MC; Bucsics, T; Chromy, D; Grabmeier-Pfistershammer, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Scheiner, B; Schwabl, P; Steiner, S; Trauner, M1
Henry, L; Hunt, S; Nader, F; Stepanova, M; Younossi, Y; Younossi, ZM1
Aghemo, A; Carrinola, R; Colombo, M; D'Ambrosio, R; Rossetti, V1
Bannan, C; Bergin, C; Coghlan, M; De Gascun, CF; Dean, J; Farrell, G; Murray, C; Sevastianova, K1
Bunnell, KL; Gallagher, MA; Glowacki, RC; Huhn, G; Osei, AM; Vibhakar, S1
Aboelwafa, AA; Elkady, EF1
Brainard, DM; Chuang, WL; Gane, E; Gao, B; Han, KH; Kao, JH; Sulkowski, MS; Yang, JC1
Bienholz, A; Eisenberger, U; Gerken, G; Guberina, H; Herzer, K; Kribben, A; Willuweit, K; Witzke, O1
Afdhal, NH; Bacon, BR; Curry, MP; Dieterich, DT; Flamm, SL; Guest, LE; Kowdley, KV; Lee, Y; Tapper, EB; Tsai, NC; Younossi, ZM1
Baumgarten, A; Berger, F; Boesecke, C; Busch, H; Christensen, S; Hueppe, D; Ingiliz, P; Kimhofer, T; Lutz, T; Mauss, S; Rockstroh, JK; Schewe, K; Schmutz, G; Schulze zur Wiesch, J; Simon, KG; Wehmeyer, MH1
Hunt, S; Mizokami, M; Omata, M; Stepanova, M; Walters, M; Younossi, ZM1
Brainard, DM; Bronowicki, JP; Brown, A; Carr, V; Dore, GJ; Grebely, J; Kreter, B; Mauss, S; Natha, M; Puoti, M; Wyles, D; Yang, J; Yun, C; Zhu, Y1
Abushouk, AI; Ahmed, H; Attia, A; Elgebaly, A; Hammad, AM; Negida, A1
Chen, J; Fang, Z; Ou, P1
Cure, S; Guerra, I; Igarashi, A; Lopresti, M; Marié, L; Tang, W1
He, QF; Zhang, DZ; Zhang, QF1
Cardoso, H; Gaspar, R; Macedo, G; Silva, M1
Fortune, BE; Lim, JK; McCarty, TR; Njei, B1
Bashir, A; Jarrad, A; Obed, A1
Davis, MM; Johnson, SW; Priest, DH; Stever, LM1
Beck, R; Berg, CP; Egetemeyr, DP; Lauer, UM; Malek, NP; Schwarz, JM; Werner, CR1
da Silveira, E; Garcia, RT; Gish, RG; Huynh, A; Levitt, B; Ly, MT; Nguyen, HA; Nguyen, KK; Nguyen, MT; Trinh, HN; Wong, RJ; Yang, J1
Henry, L; Younossi, Z1
Beck, KR; Khalili, M; Kim, N1
Assis Jarek, NA; Borba, HH; Ferreira, VL; Muzzillo, DA; Pontarolo, R; Tonin, FS; Wiens, A1
Mazzucato, M1
Bang, BR; Chopra, S; Cook, L; Elmasry, S; Feng, Z; Harper, T; Jerome, KR; Kahn, JA; Kanel, G; Kim, B; Saito, T; Wadhwa, S1
Aghemo, A; Bourlière, M; Brainard, DM; Colombo, M; Dvory-Sobol, H; Hyland, R; Liu, H; Manns, M; Massetto, B; McHutchison, JG; Peck-Radosavljevic, M; Pol, S; Yun, C; Zhang, J1
Elsheikh, E; Estep, JM; Gerber, L; Golabi, P; Karrar, A; Stepanova, M; Younossi, I; Younossi, ZM1
Buti, M; Esteban, R; Llaneras, J; Riveiro-Barciela, M1
Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Higashi, N; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K1
Bassit, L; Benhamou, Y; Chen, G; Chen, J; Hou, J; Hsiao, HM; Ji, D; Jiang, Y; Ke, R; Lau, G; Li, B; Li, F; Li, J; Liu, J; Perelson, AS; Schinazi, RF; Shao, Q; Sun, J; Tao, S; Tsang, ST; Wang, C; Wang, Y; Wong, A; Wong, CL; Wu, V1
Alonso, A; Franco, A; Gentil, MA; González-Corvillo, C; Hernández-Marrero, D; Jiménez-Martín, C; Lauzurica, LR; Perelló, M; Sánchez-Fructuoso, A; Zarraga, S1
Eurich, D; Globke, B; Pratschke, J; Raschzok, N; Schott, E; Teegen, EM1
Arterburn, S; Brainard, DM; Bzowej, NH; Dvory-Sobol, H; Hyland, RH; Levitsky, J; McHutchison, JG; Moonka, DK; O'Leary, JG; Terrault, NA; Verna, EC1
Arizumi, T; Chishina, H; Hagiwara, S; Ida, H; Iwanishi, M; Komeda, Y; Kudo, M; Minami, T; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Watanabe, T1
Hashimoto, S; Hayashida, S; Honda, M; Inomata, Y; Isono, K; Oya, Y; Sasaki, Y; Sugawara, Y; Tanaka, M; Watanabe, T; Yamamoto, H; Yoshii, D; Yoshimaru, Y1
Balistreri, WF; Bansal, S; Brainard, DM; German, P; Gonzalez-Peralta, RP; Jonas, MM; Kanwar, B; Kersey, K; Lin, CH; Massetto, B; Murray, KF; Rosenthal, P; Schwarz, K; Svarovskaia, E; Wen, J; Zhu, Y1
Buggisch, P; Chaiyakunapruk, N; Curry, MP; Jeon, CY; Kowdley, KV; Latt, NL; Lee, Y; Lott, S; Petersen, J; Qureshi, K; Sahota, A; Sundaram, V; Tsai, N1
Backstedt, D; Choi, M; Patel, A; Pedersen, MR; Seetharam, AB1
Cornberg, M; Deterding, K; Gerken, G; Hardtke, S; Klinker, H; Koch, A; Manns, MP; Papkalla, A; Pathil, A; Schott, E; Schulze Zur Wiesch, J; Spengler, U; Spinner, CD; Umgelter, A; von der Leyen, H; von Witzendorff, D; Weber, K; Wedemeyer, H; Welzel, TM; Wiegand, J; Zeuzem, S; Zöllner, C1
Chen, Y; Jiang, X; Song, Y; Tao, T1
Guerra, I; Krauth, C; Liersch, S; Rossol, S; Stahmeyer, JT1
Cameron, A; Fenkel, JM; Frank, AM; Shah, AP; Singh, P1
Allerton, M; Lai, JB; Pauly, MP; Ready, J; Seo, S; Witt, DJ; Witt, MA1
Altraif, IH1
Balba, G; Bowlus, CL; Brainard, DM; Cohen, A; Fried, MW; Han, B; Hyland, RH; Kim, AY; Kouides, P; McHutchison, JG; Reddy, KR; Rhame, F; Sax, PE; Stamm, LM; Terrault, NA; von Drygalski, A; Walsh, CE; Wang, J; Workowski, K1
Brainard, DM; Gane, EJ; Hyland, RH; McHutchison, JG; Stamm, LM; Stedman, CAM; Svarovskaia, E; Yang, Y1
Akamatsu, N; Eguchi, S; Goto, R; Ikegami, T; Kitagawa, Y; Kokudo, N; Maehara, Y; Okajima, H; Shinoda, M; Soyama, A; Taketomi, A; Ueda, Y; Uemoto, S; Yoshizumi, T1
Jansen, JW; Linneman, TW; Powderly, GM1
Chen, N; Li, X; Pan, X; Ren, H; Weng, Q; Xie, J; Xu, J1
Lim, SG1
Aikata, H; Chayama, K; Imamura, M; Ishiyama, K; Kawakami, Y; Kawaoka, T; Morio, K; Nakamura, Y; Nelson Hayes, C; Ochi, H; Ohdan, H; Tsuge, M1
Menéndez Naranjo, L; Vicente-Sánchez, S1
Ammassari, A; Antinori, A; Fabbri, G; Grisetti, S; Mastrorosa, I; Mazzotta, V; Pinnetti, C; Vergori, A; Zaccarelli, M1
Bourlière, M; Brainard, DM; Hyland, RH; Jiang, D; Marcellin, P; Pol, S; Vermehren, J; Welzel, TM; Zeuzem, S1
Chen, J; Ou, P1
Furuya, K; Iio, E; Ito, J; Izumi, T; Katagiri, M; Kawagishi, N; Kimura, M; Konno, J; Kumagai, K; Morikawa, K; Nakai, M; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shimada, N; Sho, T; Suda, G; Tanaka, Y; Tsubota, A; Umemura, M; Yamamoto, Y1
Abo-Talib, NF; El-Ghobashy, MR; Tammam, MH1
Bhamidimarri, KR; Burke, G; Chen, L; Ciancio, G; Guerra, G; Kupin, W; Ladino, M; Martin, P; Mattiazzi, A; Pedraza, F; Roth, D1
Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R1
Fernández-Cuenca, F; López-Hernández, I; Paniagua-García, M; Ríos-Villegas, MJ1
Biliotti, E; Esvan, R; Franchi, C; Palazzo, D; Serani, M; Silvestri, AM; Sorrentino, F; Spaziante, M; Taliani, G; Volpicelli, L1
Hirayama, A; Matsuoka, S; Moriyama, M; Nakamura, H; Nirei, K; Yamana, Y; Yoda, S1
Cheng, N; Ford, R; Maheshwari, R; Mgbemena, O; Norvell, JP; Parekh, S; Patel, A; Pillai, AA; Spivey, JR; Vora, R; Wedd, JP; Young, N1
Abraham, GM; Spooner, LM1
Bonfanti, P; Celesia, BM; De Socio, GV; Di Biagio, A; Maggi, P; Martinelli, C; Nicolini, LA; Quirino, T; Ricci, E; Squillace, N; Taramasso, L1
Arai, M; Chiba, T; Haga, Y; Imazeki, F; Kanda, T; Kato, N; Maruyama, H; Nakamoto, S; Nakamura, M; Ogasawara, S; Ooka, Y; Saito, T; Sasaki, R; Suzuki, E; Takahashi, K; Tawada, A; Wu, S; Yasui, S; Yokosuka, O1
Brainard, DM; Gane, EJ; Sulkowski, MS; Yang, JC1
Balkan, II; Mete, B; Ozaras, R; Tabak, F; Yemisen, M1
Brainard, DM; Hyland, RH; Lanzkron, S; McHutchison, JG; Moon, J; Sulkowski, M; Zhang, F1
Augustyniak, K; Badurek, A; Baka-Ćwierz, B; Berak, H; Białkowska, J; Flisiak, R; Garlicki, A; Gietka, A; Janczewska, E; Kozielewicz, D; Mazur, W; Mozer-Lisewska, I; Musialik, J; Nowak, K; Olszok, I; Piekarska, A; Pleśniak, R; Sikorska, K; Simon, K; Stolarz, W; Tomasiewicz, K; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D; Łucejko, M1
Furusyo, N; Hayashi, T; Murata, M; Ogawa, E; Toyoda, K; Ura, K1
Antinori, S; Binda, F; Giacomelli, A; Milazzo, L; Sollima, S; Torre, A1
Angarano, G; Bruno, G; Dell'Acqua, R; Fabrizio, C; Lo Caputo, S; Milano, E; Milella, M; Monno, L; Saracino, A; Scudeller, L1
Afdhal, NH; Bacon, B; Curry, MP; Dieterich, D; Flamm, SL; Guest, L; Kowdley, KV; Lee, Y; Milligan, S; Tapper, EB; Tsai, N; Younossi, Z1
Goda, Y; Hakamatsuka, T; Hosoe, J; Kamakura, H; Maruyama, T; Masada, S; Tokumoto, H; Tsujimoto, T; Uchiyama, N1
Brainard, DM; Lohse, AW; Mogalian, E; Scheurich, C; Schulze Zur Wiesch, J; von Felden, J; Yamamura, J1
Mansour, FR1
Andriulli, A; Barone, M; Brancaccio, G; Conti, F; Di Leo, A; Francavilla, R; Gatti, P; Iannone, A; Ippolito, AM; Lauletta, G; Masetti, C; Messina, V; Milella, M; Morisco, F; Napoli, N; Pesce, F; Santantonio, T; Shahini, E; Smedile, A; Termite, AP; Tundo, P1
Brainard, DM; Corsa, AC; Hedskog, C; Kitrinos, KM; Miller, MD; Mo, H; Worth, A1
Abutidze, A; Chkhartishvili, N; Dolmazashvili, E; Karchava, M; Sharvadze, L; Tsertsvadze, T1
Guedj, J; Kohli, A; Kottilil, S; Nguyen, THT; Perelson, AS; Uprichard, SL1
Abou-Samra, AB; Butt, AA; Simon, TG; Yan, P1
Abolmagd, E; Abouserie, AA; Attia, KA; El-Olemy, A; Salama, FM1
Anvesh, G; Rajesh, G; Raju, N; Raju, SB; Sridhar, N; Surendra, M; Vijay Kiran, B1
Chen, DS; Chen, PJ; Chen, YS; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Wang, SS; Yang, HC1
Aoki, T; Gatanaga, H; Kikuchi, Y; Kinai, E; Mizokami, M; Mizushima, D; Oka, S; Sugiyama, M; Teruya, K; Tsukada, K; Uemura, H; Watanabe, K1
Chan, HLY; Dan, YY; Kruger, E; Lee, MH; Lim, YS; Tan, SC; Younossi, ZM1
Do, S; Henry, L; Nguyen, MH; Nguyen, P; Nguyen, T; Trinh, H1
Brown, AN; Drusano, GL; Li, E; Liu, L; Neely, MN; Rodriquez, JL; Schuster, L; Wang, GP; Yamada, W; Zhao, L1
Brancaccio, G; Cantone, M; Ceccherini-Silberstein, F; Fabeni, L; Frigeri, F; Gaeta, GB; Genderini, F; Perno, CF; Pinto, A; Rizzo, V; Sorbo, MC1
Frey, A; Gerken, G; Herzer, K; Piras-Straub, K; Timm, J; Walker, A1
Agudelo, EZ; Campos-Varela, I; Roberts, JP; Sarkar, M; Terrault, NA1
Boeker, K; Buggisch, P; Günther, R; Mauss, S; Niederau, C; Pathil, A; Schott, E; Simon, KG; Teuber, G; Vermehren, J; Vornkahl, HP; Wedemeyer, H; Zeuzem, S; Zimmermann, T1
Kalal, C; Mohanka, R; Patel, P; Shah, S; Shukla, A; Vora, M1
Al-Zoairy, R; Beinhardt, S; Ferenci, P; Graziadei, I; Hofer, H; Kozbial, K; Maieron, A; Rasoul-Rockenschaub, S; Stättermayer, AF; Stauber, R; Strasser, M; Trauner, M; Zoller, H1
Allegre, T; Alric, L; Amri, I; Aumaitre, H; Bailly, F; Bellissant, E; Billaud, E; Bourlière, M; Carrieri, MP; Chas, J; Chevaliez, S; Cotte, L; De Truchis, P; Dominguez, S; Dupon, M; Fougerou-Leurent, C; Garraffo, R; Girard, PM; Jeantils, V; Lacombe, K; Leroy, V; Marcellin, F; Metivier, S; Molina, JM; Morlat, P; Naqvi, A; Neau, D; Pabic, EL; Pageaux, GP; Pailhé, A; Perré, P; Piroth, L; Poizot-Martin, I; Pol, S; Raffi, F; Renault, A; Reynes, J; Rosenthal, E; Salmon-Ceron, D; Teicher, E; Tual, C; Valantin, MA; Yazdanpanah, Y; Zucman, D1
Enomoto, M; Fujii, H; Hagihara, A; Hai, H; Kawada, N; Kozuka, R; Morikawa, H; Motoyama, H; Murakami, Y; Tamori, A; Uchida-Kobayashi, S1
Dore, GJ; Grebely, J; Hajarizadeh, B; Martinello, M; Matthews, GV1
Elhenawee, M; Hashem, H; Ibrahim, AE; Saleh, H1
Akushevich, L; Ben-Ari, Z; Fried, MW; Gallant, J; Hassan, M; Kuo, A; Landis, CS; Liapakis, AM; Lim, JK; Lok, AS; Michael, L; Nelson, DR; Park, JS; Pockros, PJ; Shiffman, ML; Terrault, NA; Vainorius, M; Zeuzem, S1
Gschwantler, M; Gutic, E; Haltmayer, H; Lang, T; Luhn, J; Moser, S; Schleicher, M; Schubert, R; Schütz, A; Schwanke, C1
Khalili, M; Mirzabeygi, V; Sohrabi, MR; Torabi Ziaratgahi, N1
Khattak, MA; Kothapalli, A1
Badr, KA; Bendas, ER; Rezk, MR1
Doi, A; Furuta, K; Hikita, H; Imai, Y; Kai, Y; Kodama, T; Mita, E; Ohkawa, K; Sakamori, R; Tahata, Y; Takehara, T; Tatsumi, T; Yakushijin, T; Yamada, R1
Desai, K; Desai, N; Kabrawala, M; Mehta, R; Nandwani, S; Parekh, V; Shah, J1
Borba, HHL; Ferreira, VL; Leonart, LP; Pontarolo, R; Tonin, FS1
Akuskevich, L; Frazier, LM; Fried, MW; Kuo, A; Levitsky, J; Li, E; Lim, JK; Liu, L; Morelli, G; Nelson, DR; Peter, J; Ramani, A; Reeves, JD; Sherman, KE; Terrault, N; Wang, GP; Zhao, L1
Goldstein, DB; Kleinstein, SE; Naggie, S; Shea, PR; Stamm, LM; Sulkowski, M1
Chamberland, S; Champsi, JH; Gittleman, LC; Hurley, LB; Korn, DG; Lai, JB; Lam, JO; Marcus, JL; Pauly, MP; Quesenberry, CP; Ready, J; Saxena, V; Seo, SI; Silverberg, MJ; Witt, DJ1
Akahane, T; Hasebe, C; Itakura, J; Izumi, N; Joko, K; Kimura, H; Kobashi, H; Kojima, Y; Kondou, M; Kurosaki, M; Kusakabe, A; Mitsuda, A; Mori, N; Nakata, R; Narita, R; Ogawa, C; Sohda, T; Takaki, S; Takezawa, J; Tamada, T; Tsuji, K; Uchida, Y; Yagisawa, H1
Benson, AA; Lederman, N; Safadi, R; Wolf, D1
Gupta, E; Kataria, A; Nayak, SL; Sarin, SK1
Easley, KA; Kalapila, AG; Kyle, AW; Michal, JL; Miller, LS; Patel, M; Rab, S1
Ojha, RP; Steyerberg, EW1
Höner Zu Siederdissen, C; Maasoumy, B1
Brainard, D; Hedskog, C; Imai, Y; Inao, M; Kouyama, JI; Mo, H; Mochida, S; Motoya, D; Naiki, K; Nakamura, S; Nakayama, N; Sugawara, K; Tomiya, T; Uchida, Y1
Gawęda, B; Kośnik, A; Krawczyk, M; Milkiewicz, P; Raszeja-Wyszomirska, J; Rejowski, S; Remiszewski, P1
Ahn, SH; Chan, HL; Chuang, WL; Han, KH; Henry, L; Kao, JH; Lai, CL; Lim, YS; Nguyen, KV; Stepanova, M; Wei, L; Younossi, ZM1
Enomoto, N; Maekawa, S1
Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N1
Abdel-Razek, W; Waked, I1
Hamano, T; Inoue, M; Someda, H; Tachibana, N; Tsuzaki, K1
El-Shorbagy, HI; Elbrashy, AM; Elsebaei, F; Hammad, SF1
Elhenawee, M; Saleh, H; Saraya, RE1
Abdel-Ghafar, TS; Abdelkareem, M; Abdelsameea, E; Abozeid, M; Alsebaey, A; Elfayomy, M; Elhelbawy, M; Fekry, M; Othman, W; Rewisha, E; Rgab, A; Sabry, A; Shebl, N; Waked, I1
Chakraborty, S; Garlapati, P; Gayam, V; Gill, A; Guss, D; Khalid, M; Mandal, AK; Mansour, M; Mohanty, S; Mukhtar, O; Sherigar, J; Shrestha, B; Tiongson, B1
Gandhi, M; Jhaveri, A; Merchant, R; Nagral, A; Nagral, N; Parikh, NS; Sawant, S1
De, A; Kumar, P; Kumari, S; Singh, A; Singh, V1
Chu, TC; MacDonald, BR; Marcus, JL; Ojha, RP1
Abid, S; Abraham, P; Abu Bakar, N; Ahmed, T; Arisar, FAQ; Bwa, AH; Chen, KP; Dan, YY; Dhore, P; Eapen, CE; Goh, KL; Hamid, S; Hj Md Said, RB; Ho, SH; Jafri, W; Kamat, M; Koshy, A; Lee, YM; Lim, SG; Madan, K; Mehta, R; Mohamed, R; Phyo, WW; Piratvisuth, T; Shah, SR; Shukla, A; Tan, SS; Tanwandee, T; Tee, HP; Tyagi, S; Wadhawan, M; Win, KM; Yang, WL; Yin, TP1
Abedi-Andani, M; Alavian, SM; Anvar, A; Behnava, B; Karimi-Sari, H; Khosravi, A; Namvar, A1
Aghemo, A; Craviotto, V; Lamonaca, L; Lleo, A1
Agarwal, K; Bruce, M; Carey, I; Spaan, M1
Biggs, BA; Kanhutu, K; Sasadeusz, J; Schulz, TR; Watkinson, S1
Cong, X; Feng, B; Jiang, HJ; Jin, Q; Luo, BF; Ma, DL; Wang, XX; Wei, L1
Angelidakis, G; Blechacz, B; Economides, MP; Granwehr, BP; Hosry, J; Jiang, Y; Kaseb, A; Kyvernitakis, A; Mahale, P; Miller, E; Naing, A; Raad, II; Samaniego, F; Torres, HA1
Enomoto, M; Hai, H; Kawada, N; Kumada, H; Okada, M; Tamori, A; Uchida-Kobayashi, S1
Issa, YM; Mohamed, SH; Salim, AI1
Chen, X; Deng, H; Hu, C; Huang, H; Li, W; Li, Y; Liu, J; Peng, Y; Ren, Y; Wu, T; Yuan, G; Zhang, YY; Zhou, Y1
Sonderup, MW; Spearman, CW1
Dohi, T; Jain, A; Kadry, Z; Krok, KL; Miller, D; Riley, TR; Schreibman, I; Sharma, R1
Baker, MM; Belal, TS; Hammad, SF1
Barreca, GS; Casalinuovo, F; Costa, C; Giancotti, A; Greco, G; Liberto, MC; Marascio, N; Matera, G; Mazzitelli, M; Pavia, G; Pisani, V; Serapide, F; Torti, C; Trecarichi, EM1
Alexander, K; Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Ellison, L; Huntley, R; Kerr, BJ; Kiser, JJ; MacBrayne, CE; MaWhinney, S1
Buggisch, P; Klinker, H; Lonjon-Domanec, I; Mauss, S; Müller, T; Nalpas, C; Pathil-Warth, A; Sarrazin, C; Schlag, M; Simon, KG; Wegner, S; Zimmermann, T1
Collado, A; Corma-Gómez, A; De Los Santos Gil, I; Granados, R; Macías, J; Merino Muñoz, D; Morano, LE; Palacios, R; Pineda, JA; Téllez, F; Vera-Méndez, FJ1
Cong, X; Feng, B; Jiang, HJ; Jin, Q; Kong, XS; Luo, BF; Qin, H; Wang, XX; Wei, L; Zhang, HY1
Asensi-Diez, R; Del Rio-Valencia, JC; Muñoz-Castillo, I; Tamayo-Bermejo, R1
Bagchi, S; Kottilil, S; Nelson, A; Poonia, B; Romani, S; Stafford, K1
Arora, S; Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Roy, A; Satsangi, S; Taneja, S1
Chen, JJ; Cheng, PN; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD1
Boglione, L; D'Avolio, A; De Nicolò, A; Di Perri, G1
Abdelaty, LN; Elnaggar, AA; Hussein, RRS; Said, AA1
Abe-Chayama, H; Aikata, H; Chayama, K; Fujino, H; Hayes, CN; Imamura, M; Kawaoka, T; Miki, D; Murakami, E; Nakahara, T; Ono, A; Osawa, M; Saito, Y; Serikawa, M; Teraoka, Y; Tsuge, M; Uchida, T1
El Atrache, LL; Labidi, A1
Amarsanaa, J; Baatarkhuu, O; Enkhtuya, D; Enkhzaya, S; Hsu, SJ; Ivshinkhorol, D; Jargalsaikhan, B; Kao, JH; Khosbayar, T; Lin, YY; Naranzul, N; Tsai, CH; Tseng, TC; Wang, TS1
Aimono, Y; Kamoshida, T; Kogo, M; Kohyama, N; Yamamoto, T2
Attia, D; El-Khayat, H; El-Shabrawi, M; Fouad, Y; Kamal, EM; Sameh, Y; Yakoot, M1
Fernández-Cuenca, F; López-Hernández, I; Palacios-Baena, ZR; Paniagua-García, M; Ríos-Villegas, MJ1
Abdel-Lateef, MA; Ali, R; Derayea, SM; Omar, MA1
Giannini, EG; Indolfi, G1
Applin, S; Asmuth, DM; Cox, S; Das, M; Goldstein, D; Guyer, B; Haubrich, RH; Hinestrosa, F; Huhn, GD; Jain, MK; Jiang, S; Nguyen-Cleary, T; Piontkowsky, D; Ramgopal, M; Rossaro, L; Ryu, JH; Slim, J1
Dholaria, B; Juskevicius, R; Moreno Vanegas, YA1
Heinz, A; Johnson, NL; Lasser, KE; Lee, KS; Quintiliani, L; Truong, V; Xuan, Z1
Abdelmalek, MO; Abu-Faddan, NH; Ibrahim, ME; Kheila, AE; Mahmoud, AA; Makhlouf, NA1
Ding, Y; Kersey, K; Li, C; Li, X; Shen, G; Zhang, H; Zhu, X1
Feng, Z; Gao, H; Huang, R; Li, Z; Liang, X; Lin, T; Liu, S; Ma, J; Wang, X; Xu, L; Zhang, L1
Chang, TS; Chen, CH; Chen, MY; Chen, WM; Chiu, WN; Hu, JH; Hu, TH; Hung, CH; Lu, CK; Lu, SN; Tung, SY; Wei, KL1
Khalil, H; Kim, NG; Kullar, R; Saab, S1
Chu, JN; Collins, J; Eweje, F; Faiz, MT; Gwynne, D; Hayward, A; Hess, K; Hua, T; Ishida, K; Katz, S; Koeppen, R; Langer, R; Lopes, A; McManus, R; Miller, JB; Salama, JAF; Slocum, AH; Soares, V; Steiger, C; Sulkowski, MS; Tamang, SM; Thomas, DL; Traverso, G; Verma, M1
Bares, SH; Havens, JP; Regan, NN1
Bruchfeld, A1
Bertrand, D; Bouvier, N; Büchler, M; Caillard, S; Chevallier, E; Colosio, C; Garrouste, C; Gatault, P; Le Meur, Y; Rerolle, JP; Rivalan, J; Rostaing, L; Sayegh, J; Thierry, A1
Chander, PN; Chugh, S; Singh, J; Solanki, S; Wolf, DC1
Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Cendali, F; Choi, YJ; Gomez, J; Haas, H; Ibrahim, ME; Johnson, B; Kiser, JJ; MaWhinney, S; Morrow, M; Roon, L; Rowan, SE; Wyles, DL; Zheng, JH1
Antonucci, R; Bartolini, E; Calvo, PL; Cananzi, M; Cangelosi, AM; D'Antiga, L; Di Dato, F; Dodi, I; Forlanini, F; Gaio, P; Garazzino, S; Giacomet, V; Indolfi, G; Iorio, R; Lenge, M; Mastrangelo, G; Nebbia, G; Nicastro, E; Nuti, F; Pinon, M; Ricci, S; Riva, S; Serranti, D; Silvestro, E; Trapani, S; Vajro, P1
Fujiyama, N; Hedskog, C; Littman, M; Liu, LJ; Mizokami, M; Ng, LJ; Sekiya, T; Yuan, J1
Chang, TT; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Wu, CH; Wu, IC; Yang, EH1
Bogen, DL; Bunge, KE; Chappell, CA; Gaggar, A; Hillier, SL; Kirby, BJ; Krans, EE; Macio, IS; Meyn, LA; Scarsi, KK; Suri, V1
Andrade, DC; Eckardt, PA; Huffman, V; Niu, J; Sherman, E1
Abo-Talib, NF; Almehizia, AA; Amr, AEE; Asiri, YA; Ezzeldin, E; Tammam, MH1
Aluzaite, K; Fraser, M; Giles, H; Johnson, S; Schultz, M1
Ahn, SH; Amarsanaa, J; Baatarkhuu, O; Badamsuren, D; Batbayar, P; Choijamts, N; Enkhtuya, D; Gantuul, C; Gegeebadrakh, B; Han, KH; Kim, DY; Lee, JS; Naranzul, N; Otgonbayar, R; Otgonbold, J; Saruul, BU; Tuvshinbayar, N; Ulzmaa, G1
Kang, SH; Kim, MY1
Bahrami, G; Hatami, R; Keshavarzi, S; Majnooni, MB; Miraghaee, SS; Mohammadi, B; Sajadimajd, S1
Abd-Elsalam, S; Abdellatif, RS; Abo-Amer, YE; Elbedewy, TA; Elsebaey, MA; Fouad, A; Mostafa, SM; Youssef, M1
Abdullatif, H; Alem, SA; El-Karaksy, H; El-Raziky, MS; Eldeen, HG; Mogahed, EA; Nagy, A; Yasin, NA1
Doi, A; Hikita, H; Kodama, T; Sakamori, R; Shigekawa, M; Shinkai, K; Tahata, Y; Takehara, T; Tatsumi, T; Yamada, R; Yamada, T1
Adeboyejo, K; Agarwal, K; Aranday-Cortes, E; Ball, JK; Cramp, ME; da Silva Filipe, A; Davis, C; Irving, WL; McClure, CP; McLauchlan, J; Mutimer, D; Sreenu, V; Stone, B; Thomson, EC; Tong, L1
Ehl, S; Maccari, ME; Speckmann, C; Thalhammer, J; Wegehaupt, O1
Rabenjanahary, TH; Rakotozafindrabe, ALR; Ramanampamonjy, RM; Randriamifidy, NH; Rasolonjatovo, AS; Razafimahefa, SH; Razafindrazoto, CI1
Aldunate, F; Chiodi, D; Cristina, J; Echeverría, N; Hernández, N; López, P; Moratorio, G; Moreno, P; Sánchez-Cicerón, A; Soñora, M1
Akhan, S; Aktuğ Demir, N; Arslan Özel, S; Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çağatay, A; Çelen, MK; Çelik, İ; Çetinkaya, RA; Demirtürk, N; Doğan, N; Ersöz, G; Gürbüz, Y; Hakyemez, İN; İnan, D; Kamalak Güzel, D; Karakeçili, F; Kınıklı, S; Konya, P; Korkmaz, P; Kuruüzüm, Z; Mıstık, R; Örmen, B; Öztürk, S; Saltoğlu, N; Şener, A; Şimşek, F; Şimşek, S; Suer, K; Tarakçı, H; Tülek, N; Tuna, N; Tuncer Ertem, G; Türker, N; Türkoğlu, E; Ural, O; Yıldız, O; Yıldız, U1
Abbassi, MM; Ebeid, FS; El-Baraky, IA; El-Sayed, MH; Hassany, M; Sabry, NA1
Biancone, L; Buggisch, P; Camargo, M; Chuang, WL; Dvory-Sobol, H; Gaggar, A; Hu, TH; Hyland, R; Kirby, BJ; Liu, CH; Lu, S; Mangia, A; Moreno, C; Osinusi, A; Peng, CY; Sise, ME; Su, WW1
Arteaga, L; Brinkley, S; Brooner, RK; Falade-Nwulia, O; Haselhuhn, T; Herne, K; Katz, S; Latkin, C; Mehta, SH; Moon, J; Sulkowski, MS; Sutcliffe, CG; Ward, KM1
Abbass, A; Abdeen, N; Afify, S; Alboraie, M; El Kassas, M; ELshazly, HM; Eltabbakh, M; Emadeldeen, M; Ezzat, S; Farghaly, R; Ghalwash, A; Hamdy, H; Omar, H; Omran, D; Salaheldin, M; Sweedy, A; Tahoon, M1
Belal, F; El-Shorbagy, HI1
Camus, G; Chang, TT; Chen, CY; Chen, JJ; Chen, PJ; Chien, RN; Chu, CJ; Chuang, WL; Gaggar, A; Hsu, YC; Hu, TH; Jiang, D; Liu, CJ; Lo, GH; Massetto, B; Peng, CY; Sheen, IS; Suri, V; Tseng, KC; Wang, HY; Yang, J; Zhang, F1
Bair, MJ; Chang, CC; Chang, TS; Chen, CH; Chen, CT; Chen, CY; Chen, GY; Cheng, PN; Chong, LW; Chuang, WL; Dai, CY; Hsieh, TY; Hsiung, CK; Hu, JT; Huang, CF; Huang, CS; Huang, JF; Huang, YH; Hung, CH; Kao, CN; Kao, JH; Kuo, HT; Lee, MH; Lee, PL; Lee, TH; Lin, CL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Wang, CC; Wang, SJ; Wu, WC; Yang, CC; Yang, SS; Yeh, ML; Yu, ML1
AlBayati, SM; Faraj, OA1
Ebeid, FSE; El-Haddad, A; El-Sayed, MH; Elsayed, W; Gaggar, A; Kersey, K; Massetto, B; Zekri, AR; Zhang, F1
Dobrzeniecka, A; Marczyńska, M; Pokorska-Śpiewak, M1
Coşar, AM; Durak, S1
Abd-Aal, MS; Abdel-Hafez, AS; Abdel-Hamid, TM; Abdel-Rahman, RZ; Abdelsalam, MFA; Elaatar, MB; Elgohary, MA; Elkady, AO; Elnagar, MT; Elnagdy, TR; Elsaied, MA; Emam, ME; Fatoh, AR; Hamada, MM; Hasan, EM; Helmy, S; Ibrahim, AA; Lotfy, HH; Mubark, MA; Nawar, OM; Sakr, MA; Seadawy, MG; Selem, MA; Shehata, MM; Zaki, AI1
Bae, SH; Chang, UI; Choi, JY; Han, JW; Jang, JW; Kim, CW; Kim, HY; Kim, SH; Kwon, JH; Lee, HL; Lee, J; Lee, SK; Lee, SW; Nam, H; Nam, SW; Song, DS; Song, MJ; Sung, PS; Yang, H; Yang, JM; Yoo, SH; Yoon, SK1
Dong, M; Evon, DM; Lok, AS; Michael, L; Nelson, DR; Peter, J; Reeve, BB; Stewart, PW1
Abd Elghafar, MS; Abd-Elsalam, S; Abdelghaffar, H; Abdelghaffar, K; Al Shafie, A; Badr, M; El-Kassas, M; Esmael, HE; Ezz Eldin, AM; Ezzat, S; Hassany, SM; Kamal, DT; Karam-Allah, H; Medhat, MA; Moaz, I; Moustafa, E; Ossimi, A; Salama, M; Sayed, H; Shamseldeen, A1
Abdine, HH; Aboras, SI; El-Yazbi, AF; Korany, MA; Ragab, MAA1
Abdelaziz, A; Abdelgaied, MY; Abdelkawy, KS; Belal, F; El-Khodary, NM; Elmekawy, HA1
AbouBakr, O; El Sayed Zaki, M; Ezz El Regal, M; Noaman, A; Sarhan, AA1
Chua, JV; Ghosh, A; Kottilil, S; Nelson, AK; Price, AS1
Fujita, K; Manabe, T; Masaki, T; Morishita, A; Nakahara, M; Ogawa, C; Ohura, K; Tadokoro, T; Tani, J1
Hung, A; Seetasith, A; Wong, WB; Zullig, LL1
Anderson, KE; Bonkovsky, HL; Faust, D; Hallberg, C; Hedstrom, K; Ma, CD; Moghe, A; Naik, H; Overbey, JR; Rudnick, SP; Wang, K1
Ayadi, S; Ayari, M; Ghithia, N; Zaimi, Y1
Charlton, C; Hlavay, BA; Klein, MB; Ogando, N; Power, C; Stapleton, JT; Zhuo, R1

Reviews

35 review(s) available for sofosbuvir and ledipasvir

ArticleYear
Hepatitis C - New drugs and treatment prospects.
    European journal of medicinal chemistry, 2019, Mar-01, Volume: 165

    Topics: Animals; Antiviral Agents; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Hepatitis C; Humans; Molecular Structure; Molecular Targeted Therapy; Protease Inhibitors

2019
Interferon-free strategies with a nucleoside/nucleotide analogue.
    Seminars in liver disease, 2014, Volume: 34, Issue:1

    Topics: Animals; Antiviral Agents; Benzimidazoles; Drug Design; Drug Resistance, Viral; Fluorenes; Hepacivirus; Hepatitis C; Humans; Interferons; Molecular Targeted Therapy; Nucleosides; Nucleotides; Protease Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Hepatitis C management in post-transplant patients.
    Minerva gastroenterologica e dietologica, 2015, Volume: 61, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load

2015
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:47

    Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Combinations; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine

2014
Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:3

    Topics: Adult; Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Nausea; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Precision Medicine; Pyrrolidines; Sofosbuvir; Uridine Monophosphate; Valine

2015
Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Meta-Analysis as Topic; Recurrence; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2015
Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.
    Drugs, 2015, Volume: 75, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Sofosbuvir

2015
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
    Orvosi hetilap, 2015, May-24, Volume: 156, Issue:21

    Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Proline; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins; Virus Replication

2015
Ideal oral combinations to eradicate HCV: The role of ribavirin.
    Journal of hepatology, 2016, Volume: 64, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Valine

2016
Does herbal medicine reduce the risk of hepatocellular carcinoma?
    World journal of gastroenterology, 2015, Oct-07, Volume: 21, Issue:37

    Topics: Animals; Anti-Inflammatory Agents; Benzimidazoles; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cysteine; Drug Combinations; Drugs, Chinese Herbal; Fatty Liver; Fluorenes; Glycine; Glycyrrhetinic Acid; Glycyrrhizic Acid; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Phytotherapy; Plant Preparations; Sofosbuvir; Tablets

2015
Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.
    Expert review of gastroenterology & hepatology, 2015, Volume: 9, Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance, Viral; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir

2015
Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
    Expert review of anti-infective therapy, 2016, Volume: 14, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Disease Management; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2016
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1

    Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins

2016
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir

2016
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C.
    Expert opinion on drug safety, 2016, Volume: 15, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Safety; Sofosbuvir

2016
A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients.
    International journal of antimicrobial agents, 2016, Volume: 47, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Models, Theoretical; Pyrrolidines; Simeprevir; Sofosbuvir; Valine

2016
Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection.
    Pharmacotherapy, 2016, Volume: 36, Issue:5

    Topics: Administration, Oral; Benzimidazoles; Drug Combinations; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Sofosbuvir

2016
Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection.
    Drugs of today (Barcelona, Spain : 1998), 2016, Volume: 52, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir

2016
Sexually-transmitted seronegative HCV infection in an HIV-positive post-liver transplant recipient. Case report and review of the literature.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2016, Volume: 79

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Liver Transplantation; Male; Middle Aged; RNA, Viral; Sexually Transmitted Diseases, Viral; Sofosbuvir; Transaminases; Transplant Recipients; Treatment Outcome

2016
Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:11

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Lung Transplantation; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.
    Antiviral therapy, 2017, Volume: 22, Issue:5

    Topics: Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Publication Bias; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2017
Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.
    Digestive diseases and sciences, 2016, Volume: 61, Issue:11

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2016
Rapid Virological Response After Early Treatment with a Combined Therapy of Ledipasvir and Sofosbuvir in HCV Genotype 4 After Living Donor Liver Transplantation in a HCC Downstaged Patient: Case Report and Review of the Literature.
    The American journal of case reports, 2016, Sep-20, Volume: 17

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Sofosbuvir

2016
Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C.
    Expert review of pharmacoeconomics & outcomes research, 2016, Volume: 16, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Fluorenes; Hepatitis C, Chronic; Humans; Medication Adherence; Sofosbuvir; Treatment Outcome; United States

2016
Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Databases, Bibliographic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Hepatitis C virus genotype 4: Genotype 1's little brother.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Simeprevir; Sofosbuvir; Sustained Virologic Response

2017
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.
    Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:4

    Topics: Adult; Benzimidazoles; Biopsy, Needle; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Recurrence; Risk Assessment; Severity of Illness Index; Sofosbuvir; Time Factors; Treatment Outcome

2017
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017, Volume: 55

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature.
    Oncotarget, 2017, Mar-28, Volume: 8, Issue:13

    Topics: Aged; Anti-Inflammatory Agents; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Glomerulonephritis, Membranous; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prednisolone; Prognosis; Sofosbuvir

2017
HCV management in resource-constrained countries.
    Hepatology international, 2017, Volume: 11, Issue:3

    Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine

2017
Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
    BMC infectious diseases, 2017, 03-01, Volume: 17, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; HIV Infections; Humans; Middle Aged; Sofosbuvir

2017
Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies.
    Clinical drug investigation, 2018, Volume: 38, Issue:5

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine

2018
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
    Clinical and molecular hepatology, 2018, Volume: 24, Issue:3

    Topics: Benzimidazoles; Carbamates; Dose-Response Relationship, Drug; Drug Interactions; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Kidney; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Sulfonamides; Valine

2018
Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:8

    Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Cyclopropanes; Disease Eradication; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Pediatrics; Proline; Pyrrolidines; Quality of Life; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; World Health Organization

2020

Trials

60 trial(s) available for sofosbuvir and ledipasvir

ArticleYear
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
    Lancet (London, England), 2014, Feb-08, Volume: 383, Issue:9916

    Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Protease Inhibitors; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
    Gastroenterology, 2014, Volume: 146, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Enzyme Inhibitors; Fatigue; Female; Fluorenes; Furans; Genotype; Headache; Hepacivirus; Hepatitis C; Humans; Incidence; Male; Middle Aged; Nausea; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
    The New England journal of medicine, 2014, May-15, Volume: 370, Issue:20

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult

2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
    The New England journal of medicine, 2014, Apr-17, Volume: 370, Issue:16

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Nucleotidyltransferases; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Load; Viral Nonstructural Proteins

2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
    The New England journal of medicine, 2014, May-15, Volume: 370, Issue:20

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult

2014
Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Antiviral Agents; Base Sequence; Benzimidazoles; Cell Line; Drug Resistance, Viral; Female; Fluorenes; Furans; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Protein Binding; Quinolines; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.
    Annals of internal medicine, 2014, Nov-04, Volume: 161, Issue:9

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutation; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate

2014
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Male; Middle Aged; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Load

2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
    The Lancet. Infectious diseases, 2015, Volume: 15, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult

2015
The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Monitoring; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Outcome Assessment; Ribavirin; RNA, Viral; Sofosbuvir

2016
Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Adult; Antiviral Agents; Benzimidazoles; Chemokine CXCL10; Convalescence; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Protein Processing, Post-Translational; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load; Virus Replication

2015
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.
    The Lancet. Infectious diseases, 2015, Volume: 15, Issue:9

    Topics: Aged; Benzimidazoles; DNA, Viral; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Viral Load

2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
    The New England journal of medicine, 2015, Aug-20, Volume: 373, Issue:8

    Topics: Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load

2015
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gastroenterology, 2015, Volume: 149, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; New Zealand; Random Allocation; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2015
Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:12

    Topics: Antiviral Agents; Apolipoproteins; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2015
Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Feb-15, Volume: 62, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Quinolines; Sofosbuvir; Treatment Outcome; Young Adult

2016
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Feb-01, Volume: 62, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Retreatment; Sequence Analysis, DNA; Sofosbuvir; Treatment Outcome; Viral Load; Viral Nonstructural Proteins

2016
Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
    AIDS research and human retroviruses, 2016, Volume: 32, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cholesterol, LDL; Coinfection; Drug Therapy, Combination; Dyslipidemias; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolines; Ribavirin; Sofosbuvir; Thiophenes; Uridine Monophosphate

2016
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.
    Annals of internal medicine, 2015, Dec-15, Volume: 163, Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Furans; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quinolines; RNA, Viral; Sofosbuvir; Thiophenes; Treatment Outcome; Viral Load

2015
Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.
    AIDS (London, England), 2016, Volume: 30, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Sofosbuvir; Urban Population

2016
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    The Lancet. Infectious diseases, 2016, Volume: 16, Issue:4

    Topics: Administration, Oral; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load

2016
Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.
    Journal of the American Geriatrics Society, 2016, Volume: 64, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.
    Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:7

    Topics: Adult; Aged; Benzimidazoles; Carbamates; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Tablets; Taiwan; Treatment Outcome

2016
An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Patient Reported Outcome Measures; Retrospective Studies; Ribavirin; Sofosbuvir

2016
Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:11

    Topics: Adult; Antiviral Agents; Benzimidazoles; Efficiency; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Patient Satisfaction; Sofosbuvir; Treatment Outcome

2016
Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies.
    Antiviral therapy, 2016, Volume: 21, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir

2016
No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 11-01, Volume: 63, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Virus Activation

2016
Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 11-15, Volume: 63, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Germany; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Sofosbuvir; Viral Load; Young Adult

2016
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Dec-01, Volume: 63, Issue:11

    Topics: Adult; Antiviral Agents; Benzimidazoles; Data Interpretation, Statistical; Drug Therapy, Combination; Drug Users; Enzyme-Linked Immunosorbent Assay; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Opiate Substitution Treatment; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load

2016
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.
    Annals of internal medicine, 2017, Jan-17, Volume: 166, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Sofosbuvir

2017
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Intention to Treat Analysis; Isoquinolines; Male; Middle Aged; Proof of Concept Study; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load

2016
Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients.
    The New England journal of medicine, 2016, 11-24, Volume: 375, Issue:21

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Transplantation; Perioperative Care; RNA, Viral; Sofosbuvir

2016
Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation.
    Bioscience trends, 2017, Jan-16, Volume: 10, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Pilot Projects; Sofosbuvir; Treatment Outcome

2017
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:2

    Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Patient Safety; Risk Assessment; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Viral Load

2017
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Germany; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Prospective Studies; RNA, Viral; Sofosbuvir

2017
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
    Gastroenterology, 2017, Volume: 152, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Fatigue; Female; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Nausea; Sofosbuvir; Sustained Virologic Response

2017
Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins

2018
The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
    Scientific reports, 2017, 08-31, Volume: 7, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Models, Theoretical; Quinolines; Sofosbuvir; Sustained Virologic Response; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Load

2017
Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
    PloS one, 2017, Volume: 12, Issue:10

    Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Interferons; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sofosbuvir; Valine; Viral Load

2017
Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients.
    The American journal of gastroenterology, 2017, Volume: 112, Issue:12

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response

2017
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
    HIV medicine, 2018, Volume: 19, Issue:3

    Topics: Aged; Benzimidazoles; Coinfection; Drug Administration Schedule; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Pilot Projects; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutation, Missense; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins

2018
Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers.
    Clinical drug investigation, 2018, Volume: 38, Issue:5

    Topics: Adolescent; Adult; Area Under Curve; Benzimidazoles; Chromatography, Liquid; Cross-Over Studies; Drug Compounding; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Healthy Volunteers; Humans; Male; Middle Aged; Reference Standards; Sofosbuvir; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency; Young Adult

2018
Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 06-01, Volume: 66, Issue:12

    Topics: Alkynes; Antiviral Agents; Benzimidazoles; Benzoxazines; Black or African American; Cohort Studies; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Therapy, Combination; Female; Fluorenes; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Polymorphism, Single Nucleotide; Recurrence; Sofosbuvir

2018
Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; China; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Quality of Life; Republic of Korea; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Taiwan; Treatment Outcome

2018
Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:10

    Topics: 2-Naphthylamine; Adult; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load

2018
Peripheral PD-1
    Frontiers in immunology, 2019, Volume: 10

    Topics: Adult; Antiviral Agents; Benzimidazoles; CD8-Positive T-Lymphocytes; Cytokines; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pilot Projects; Programmed Cell Death 1 Receptor; Quinolines; Receptors, Immunologic; Sofosbuvir; Sustained Virologic Response; T-Lymphocytes; Thiophenes; Viral Load

2019
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
    Journal of hepatology, 2019, Volume: 71, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Clinical Protocols; Delivery of Health Care; Disease Eradication; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; India; Liver Cirrhosis; Male; Public Health; Ribavirin; Sofosbuvir; Sustained Virologic Response; Telemedicine

2019
Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Treatment Outcome

2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
    PloS one, 2020, Volume: 15, Issue:1

    Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Sofosbuvir; Tenofovir

2020
Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.
    Clinical therapeutics, 2020, Volume: 42, Issue:3

    Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; China; Female; Fluorenes; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir

2020
Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study.
    Journal of pediatric gastroenterology and nutrition, 2021, 01-01, Volume: 72, Issue:1

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Prospective Studies; Sofosbuvir; Treatment Outcome

2021
Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study.
    The Lancet. Microbe, 2020, Volume: 1, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Infant; Pregnancy; Pregnant Women; Sofosbuvir; Treatment Outcome

2020
Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs.
    The Journal of infectious diseases, 2022, 03-02, Volume: 225, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Pharmaceutical Preparations; Sofosbuvir; Substance-Related Disorders; Sustained Virologic Response; Treatment Outcome

2022
Ledipasvir-sofosbuvir in Adolescents With Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy.
    Journal of pediatric gastroenterology and nutrition, 2022, 05-01, Volume: 74, Issue:5

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Diarrhea; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hematologic Neoplasms; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Treatment Outcome

2022
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.
    Journal of medicine and life, 2022, Volume: 15, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2022
Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.
    Journal of viral hepatitis, 2022, Volume: 29, Issue:9

    Topics: Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Sofosbuvir; Sulfonamides

2022
Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2022, Volume: 23, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Repositioning; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Humans; Nitro Compounds; SARS-CoV-2; Sofosbuvir; Thiazoles; Treatment Outcome; Viral Load

2022
Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein.
    Drug research, 2022, Volume: 72, Issue:6

    Topics: Antiviral Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Biological Availability; Cross-Over Studies; Drug Combinations; Fluorenes; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Sofosbuvir

2022
A Phase 2 open label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infection.
    Journal of medical virology, 2023, Volume: 95, Issue:1

    Topics: Antiviral Agents; DNA, Viral; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Pilot Projects; Retrospective Studies; Sofosbuvir; Symptom Flare Up

2023

Other Studies

221 other study(ies) available for sofosbuvir and ledipasvir

ArticleYear
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Therapy for hepatitis C--the costs of success.
    The New England journal of medicine, 2014, Apr-17, Volume: 370, Issue:16

    Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Uridine Monophosphate

2014
Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
    Antiviral research, 2014, Volume: 107

    Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Drug Discovery; Fluorenes; Hepatitis C, Chronic; Humans; Nucleosides; Nucleotides; Sofosbuvir; Uridine Monophosphate

2014
Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:11

    Topics: Adult; Antiviral Agents; Area Under Curve; Benzimidazoles; Contraceptives, Oral, Combined; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Fluorenes; Half-Life; Hepacivirus; Humans; Norgestrel; Sofosbuvir; Uridine Monophosphate

2014
Sovaldi dilemma likely to get worse.
    Managed care (Langhorne, Pa.), 2014, Volume: 23, Issue:9

    Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Fluorenes; Hepatitis C; Humans; Prescription Fees; Sofosbuvir; United States; Uridine Monophosphate

2014
A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
    The Medical letter on drugs and therapeutics, 2014, Nov-10, Volume: 56, Issue:1455

    Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Drug Combinations; Drug Interactions; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate

2014
Gilead's interferon-free HCV combo approved.
    Nature biotechnology, 2014, Volume: 32, Issue:11

    Topics: Benzimidazoles; Drug Approval; Drug Combinations; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Sofosbuvir; United States; United States Food and Drug Administration

2014
Shorter treatments for hepatitis C: another step forward?
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Furans; Hepatitis C, Chronic; Humans; Male; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Uridine Monophosphate

2015
Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Costs and Cost Analysis; Efficiency; Fluorenes; Hepatitis C, Chronic; Humans; Models, Economic; Sofosbuvir; United States; Uridine Monophosphate

2015
Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Randomized Controlled Trials as Topic; Recurrence; Sofosbuvir; Uridine Monophosphate

2015
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
    Annals of internal medicine, 2015, Mar-17, Volume: 162, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Budgets; Cost-Benefit Analysis; Drug Costs; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Interferon-alpha; Markov Chains; Patient-Specific Modeling; Quality-Adjusted Life Years; Sofosbuvir; United States; Uridine Monophosphate

2015
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
    Journal of hepatology, 2015, Volume: 63, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Sofosbuvir; Surveys and Questionnaires

2015
Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada.
    Canadian journal of gastroenterology & hepatology, 2015, Volume: 29, Issue:3

    Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Eligibility Determination; Fluorenes; Health Services Accessibility; Hepatitis C, Chronic; Humans; Mathematical Computing; Ontario; Reproducibility of Results; Research Design; Risk Assessment; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2015
Thousands of patients in England to get new hepatitis C drugs.
    BMJ (Clinical research ed.), 2015, Jun-12, Volume: 350

    Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; England; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Public Health; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine

2015
Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:11

    Topics: Antiviral Agents; Bayes Theorem; Benzimidazoles; Clinical Trials as Topic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Statistical; Sofosbuvir

2015
Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
    Journal of gastroenterology, 2015, Volume: 50, Issue:11

    Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Multiple, Viral; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Hepatitis, Viral, Animal; Hepatocytes; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sulfonamides; Transplantation Chimera; Treatment Failure; Valine

2015
Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2016, Volume: 14, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Biomarkers; Blood Chemical Analysis; Cytokines; Enzyme-Linked Immunosorbent Assay; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Acute liver failure during hepatitis C treatment with sofosbuvir and ledipasvir.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:12

    Topics: Acute-On-Chronic Liver Failure; Aged; Antiviral Agents; Benzimidazoles; End Stage Liver Disease; Fatal Outcome; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Sofosbuvir

2015
No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; RNA, Viral; Sofosbuvir; Time Factors

2016
Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Disease Eradication; Efficiency; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Models, Economic; Sofosbuvir; Surveys and Questionnaires; Young Adult

2016
Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Combinations; Fluorenes; Hepatitis C, Chronic; Humans; Middle Aged; Quality-Adjusted Life Years; Sofosbuvir; United States; Veterans Health

2016
Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
    JAMA internal medicine, 2016, Volume: 176, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Middle Aged; Quality-Adjusted Life Years; Severity of Illness Index; Sofosbuvir; Treatment Outcome; United States; Viral Load; Young Adult

2016
Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:5

    Topics: Aged; Antiviral Agents; Benzimidazoles; Comorbidity; Databases, Factual; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States

2016
Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2016, Jan-01, Volume: 1008

    Topics: Animals; Antiviral Agents; Benzimidazoles; Chromatography, Liquid; Fluorenes; Male; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sofosbuvir; Tandem Mass Spectrometry

2016
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Patient Safety; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Risk Assessment; Sex Factors; Sofosbuvir; Treatment Outcome

2016
Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
    Journal of comparative effectiveness research, 2016, Volume: 5, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Valine

2016
Myo-pericarditis secondary to ledipasvir-sofosbuvir therapy.
    Journal of hepatology, 2016, Volume: 64, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Echocardiography; Electrocardiography; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Male; Middle Aged; Myocarditis; Pericarditis; Sofosbuvir

2016
Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Ohio; Renal Dialysis; Simeprevir; Sofosbuvir; Sustained Virologic Response

2016
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.
    Antimicrobial agents and chemotherapy, 2016, Jan-11, Volume: 60, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Carrier Proteins; Cell Line, Tumor; Drug Combinations; Drug Resistance, Viral; Drug Synergism; Fluorenes; Genotype; HeLa Cells; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Microbial Sensitivity Tests; Sofosbuvir; Viral Nonstructural Proteins

2016
HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.
    Journal of hepatology, 2016, Volume: 64, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Kinetics; Male; Middle Aged; Models, Theoretical; Pyrrolidines; Retrospective Studies; RNA, Viral; Simeprevir; Sofosbuvir; Time Factors; Valine

2016
Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir.
    Medicine, 2016, Volume: 95, Issue:9

    Topics: Antiviral Agents; Asia; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Outcome Assessment; Quality of Life; Sofosbuvir; Surveys and Questionnaires

2016
Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
    Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:3

    Topics: Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Streptococcus salivarius spontaneous bacterial peritonitis in a HIV/HCV-co-infected patient treated with direct antiviral agents.
    Enfermedades infecciosas y microbiologia clinica, 2017, Volume: 35, Issue:3

    Topics: Anti-Bacterial Agents; Antiviral Agents; Bacterial Translocation; Benzimidazoles; Ceftriaxone; Coinfection; Disease Susceptibility; Esophageal and Gastric Varices; Esophagoscopy; Female; Fluorenes; Gastrointestinal Hemorrhage; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Middle Aged; Peritonitis; Sofosbuvir; Streptococcus salivarius; Substance Abuse, Intravenous

2017
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
    Journal of medical economics, 2016, Volume: 19, Issue:8

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Econometric; Proline; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine

2016
Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:5

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pruritus; Pyrrolidines; Recurrence; Simeprevir; Sleep Initiation and Maintenance Disorders; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2016
DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
    Transplant international : official journal of the European Society for Organ Transplantation, 2016, Volume: 29, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Kidney; Kidney Function Tests; Kidney Transplantation; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Period; Preoperative Period; Pyrrolidines; Renal Dialysis; Renal Insufficiency; RNA, Viral; Simeprevir; Sofosbuvir; Valine

2016
Hepatotoxicity and potential drug interaction with ledipasvir/sofosbuvir in HIV/HCV infected patients.
    Journal of hepatology, 2016, Volume: 65, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Therapy, Combination; Fluorenes; Hepatitis C; HIV Infections; Humans; Sofosbuvir

2016
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 08-15, Volume: 63, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Middle Aged; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Treatment Failure

2016
Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis.
    Journal of pediatric gastroenterology and nutrition, 2016, Volume: 63, Issue:5

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Sofosbuvir; Viral Load

2016
Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Directly Observed Therapy; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Pyrrolidines; Severity of Illness Index; Sofosbuvir; Substance Abuse Treatment Centers; Valine

2016
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.
    PloS one, 2016, Volume: 11, Issue:6

    Topics: Asian People; Benzimidazoles; China; Costs and Cost Analysis; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Markov Chains; Models, Economic; Sofosbuvir

2016
Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.
    Alimentary pharmacology & therapeutics, 2016, Volume: 44, Issue:4

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult

2016
Quantification of sofosbuvir and ledipasvir in human plasma by UPLC-MS/MS method: Application to fasting and fed bioequivalence studies.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2016, Aug-15, Volume: 1028

    Topics: Adult; Antiviral Agents; Benzimidazoles; Chromatography, High Pressure Liquid; Fasting; Female; Fluorenes; Humans; Limit of Detection; Male; Middle Aged; Sofosbuvir; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Therapeutic Equivalency; Young Adult

2016
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
    Advances in therapy, 2016, Volume: 33, Issue:8

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil; Valine

2016
Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:4

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Time Factors; Treatment Outcome

2016
Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
    Journal of medical virology, 2017, Volume: 89, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Retreatment; Retrospective Studies; Sofosbuvir; Treatment Outcome; Young Adult

2017
Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV.
    Antiviral therapy, 2016, Volume: 21, Issue:7

    Topics: Aged; Antiviral Agents; Benzimidazoles; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepatitis B; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir

2016
Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.
    Medicine, 2016, Volume: 95, Issue:27

    Topics: Antiviral Agents; Austria; Benzimidazoles; Carbamates; Coinfection; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Quality of Life; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Valine

2016
Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.
    Medicine, 2016, Volume: 95, Issue:28

    Topics: Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Middle Aged; Multicenter Studies as Topic; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir

2016
NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2016, Volume: 82

    Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Middle Aged; Mutation, Missense; Ribavirin; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins

2016
Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
    Pharmacotherapy, 2016, Volume: 36, Issue:9

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C; HIV Infections; Humans; Kidney; Middle Aged; Sofosbuvir; Tenofovir

2016
A Rapid and Optimized LC-MS/MS Method for the Simultaneous Extraction and Determination of Sofosbuvir and Ledipasvir in Human Plasma.
    Journal of AOAC International, 2016, Volume: 99, Issue:5

    Topics: Benzimidazoles; Chromatography, Liquid; Fluorenes; Humans; Molecular Structure; Sofosbuvir; Tandem Mass Spectrometry

2016
Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients.
    Transplantation, 2017, Volume: 101, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Sofosbuvir; Treatment Outcome

2017
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Interactions; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir.
    Medicine, 2016, Volume: 95, Issue:33

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires

2016
Hepatitis B reactivation in a chronic hepatitis C patient treated with ledipasvir and sofosbuvir: A case report.
    Clinics and research in hepatology and gastroenterology, 2017, Volume: 41, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepatitis B; Hepatitis C, Chronic; Humans; Recurrence; Sofosbuvir; Time Factors; Treatment Outcome

2017
Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
    Current medical research and opinion, 2017, Volume: 33, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir

2017
Curing HCV infection with 4 weeks-regimen of sofosbuvir and ledipasvir: To be remembered.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Middle Aged; Sofosbuvir

2016
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
    Alimentary pharmacology & therapeutics, 2016, Volume: 44, Issue:10

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States

2016
Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual.
    Journal of clinical pharmacy and therapeutics, 2016, Volume: 41, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Sofosbuvir; Treatment Outcome

2016
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
    World journal of gastroenterology, 2016, Sep-21, Volume: 22, Issue:35

    Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine

2016
Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Young Adult

2017
Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
    Digestive diseases and sciences, 2016, Volume: 61, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Pyrrolidines; Retrospective Studies; Ribavirin; San Francisco; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Vulnerable Populations; Young Adult

2016
High cost of new drugs.
    BMJ (Clinical research ed.), 2016, Jul-27, Volume: 354

    Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Costs; Drug Industry; Fluorenes; Hepatitis C; Humans; Sofosbuvir; United Kingdom

2016
Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
    Gastroenterology, 2017, Volume: 152, Issue:3

    Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load; Virus Replication

2017
The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV).
    Medicine, 2016, Volume: 95, Issue:46

    Topics: Affective Symptoms; Antiviral Agents; Benzimidazoles; Biomarkers; Cytokines; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Mental Disorders; Middle Aged; Neurotransmitter Agents; Retrospective Studies; Ribavirin; Sofosbuvir

2016
NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    Journal of gastroenterology, 2017, Volume: 52, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Risk Factors; Sex Factors; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins; Young Adult

2017
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
    Transplantation proceedings, 2016, Volume: 48, Issue:9

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppression Therapy; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Postoperative Complications; Proline; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Sulfonamides; Treatment Outcome; Valine

2016
Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir

2017
Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver Disease.
    Oncology, 2017, Volume: 92 Suppl 1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome

2017
Genotype specific peripheral lipid profile changes with hepatitis C therapy.
    World journal of gastroenterology, 2016, Dec-14, Volume: 22, Issue:46

    Topics: Aged; Alanine Transaminase; Antiviral Agents; Benzimidazoles; Cholesterol; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Triglycerides

2016
Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
    PloS one, 2017, Volume: 12, Issue:1

    Topics: Adult; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Markov Chains; Middle Aged; Models, Theoretical; Public Health; Quality of Life; Quality-Adjusted Life Years; Sensitivity and Specificity; Sofosbuvir

2017
Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:2

    Topics: Acetaminophen; Adult; Allografts; Antiviral Agents; Benzimidazoles; Blood-Borne Pathogens; Chemical and Drug Induced Liver Injury; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Viral Load

2017
Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System.
    Drugs, 2017, Volume: 77, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Delivery of Health Care, Integrated; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Time Factors

2017
Sofosbuvir plus ledipasvir for recurrent hepatitis C in liver transplant recipients.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2017, Volume: 23, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Transplantation; Sofosbuvir

2017
Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2017, Volume: 23, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult

2017
Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
    Journal of gastroenterology, 2017, Volume: 52, Issue:8

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Transplantation; Living Donors; Male; Middle Aged; Postoperative Period; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins

2017
Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:7

    Topics: Aged; Antiviral Agents; Benzimidazoles; Case-Control Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Odds Ratio; Retrospective Studies; Sofosbuvir; Treatment Failure; Treatment Outcome; Viral Load

2017
Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
    Clinical journal of gastroenterology, 2017, Volume: 10, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; RNA, Viral; Sofosbuvir; Viral Load

2017
[Debut in diabetic patients with hepatitis C treatment with ledipasvir/ sofosbuvir (Harvoni®)].
    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2017, 03-01, Volume: 41, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Diabetes Complications; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir

2017
Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2017, Volume: 89

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Automation, Laboratory; Benzimidazoles; Drug Monitoring; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Molecular Diagnostic Techniques; RNA, Viral; Sofosbuvir; Viral Load; Young Adult

2017
Hepatitis B reactivation in chronic hepatitis C patients during treatment with ledipasvir and sofosbuvir.
    Antiviral therapy, 2018, Volume: 23, Issue:3

    Topics: Benzimidazoles; Coinfection; Fluorenes; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir

2018
Author reply to: Hepatitis B reactivation in chronic hepatitis C patients during treatment with ledipasvir and sofosbuvir.
    Antiviral therapy, 2018, Volume: 23, Issue:3

    Topics: Benzimidazoles; Coinfection; Fluorenes; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir

2018
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    Journal of gastroenterology, 2017, Volume: 52, Issue:10

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine

2017
Spectrophotometric Methods for Simultaneous Determination of Sofosbuvir and Ledipasvir (HARVONI Tablet): Comparative Study with Two Generic Products.
    Journal of AOAC International, 2017, Jul-01, Volume: 100, Issue:4

    Topics: Benzimidazoles; Drugs, Generic; Fluorenes; Sofosbuvir; Tablets; Therapeutic Equivalency; Uridine Monophosphate

2017
Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Transplant international : official journal of the European Society for Organ Transplantation, 2017, Volume: 30, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Donor Selection; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Postoperative Care; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Tissue Donors; Treatment Outcome; Valine

2017
Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Nephrology (Carlton, Vic.), 2018, Volume: 23, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; India; Kidney Diseases; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load

2018
Acute fulminant hepatitis B during hepatitis C virus therapy with direct-acting antivirals in a patient co-infected with HIV.
    Enfermedades infecciosas y microbiologia clinica, 2017, Volume: 35, Issue:10

    Topics: Anti-HIV Agents; Antiviral Agents; Benzimidazoles; Coinfection; Drug Substitution; Fatal Outcome; Fluorenes; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Liver Failure, Acute; Male; Middle Aged; Oligopeptides; Ribavirin; Sofosbuvir; Virus Activation

2017
Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major.
    Annals of hematology, 2017, Volume: 96, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Benzoates; beta-Thalassemia; Cryoglobulinemia; Deferasirox; Deferoxamine; Elasticity Imaging Techniques; Female; Ferritins; Fluorenes; Hepatitis C, Chronic; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis; Male; Quality of Life; Sofosbuvir; Triazoles; Viral Load

2017
Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection.
    Internal medicine (Tokyo, Japan), 2017, Volume: 56, Issue:7

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C; Humans; Risk Factors; Sofosbuvir; Tachycardia, Ventricular

2017
Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:11

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Logistic Models; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Load

2017
Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2017, 04-15, Volume: 74, Issue:8

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load

2017
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?
    Clinics and research in hepatology and gastroenterology, 2017, Volume: 41, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Tenofovir; Treatment Outcome

2017
Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4
    International journal of molecular sciences, 2017, Apr-25, Volume: 18, Issue:5

    Topics: Aged; Antiviral Agents; Asian People; Benzimidazoles; Carrier Proteins; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Intracellular Signaling Peptides and Proteins; Japan; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins

2017
Reply to Ozaras et al.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, 05-15, Volume: 64, Issue:10

    Topics: Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis B virus; Humans; Sofosbuvir

2017
Reactivation of Hepatitis B Virus Following Treatment of Hepatitis C Virus Infection in Coinfected Patients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, 05-15, Volume: 64, Issue:10

    Topics: Benzimidazoles; Coinfection; Fluorenes; Hepacivirus; Hepatitis B virus; Hepatitis C; HIV Infections; Humans; Sofosbuvir

2017
Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Sep-01, Volume: 65, Issue:5

    Topics: Adult; Anemia, Sickle Cell; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Young Adult

2017
Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
    Advances in medical sciences, 2017, Volume: 62, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Safety; Sofosbuvir; Treatment Outcome

2017
Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome; Virus Activation

2018
Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient.
    International journal of STD & AIDS, 2017, Volume: 28, Issue:8

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Fluorenes; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome

2017
The elderly and direct antiviral agents: Constraint or challenge?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:9

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Logistic Models; Male; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2017
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:5

    Topics: Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Chemical Analysis of Counterfeit Hepatitis C Drug Found in Japan.
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2017, 10-01, Volume: 137, Issue:10

    Topics: Antiviral Agents; Benzimidazoles; Chromatography, Liquid; Counterfeit Drugs; Drugs, Chinese Herbal; Ephedrine; Fluorenes; Gas Chromatography-Mass Spectrometry; Glycyrrhizic Acid; Hepatitis C; Japan; Magnetic Resonance Spectroscopy; Mass Spectrometry; Sofosbuvir; Tablets; Uridine Monophosphate; Vitamins

2017
Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Crohn Disease; Fluorenes; Hepatitis C, Chronic; Humans; Short Bowel Syndrome; Sofosbuvir

2018
A new innovative spectrophotometric method for the simultaneous determination of sofosbuvir and ledipasvir.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2018, Jan-05, Volume: 188

    Topics: Benzimidazoles; Calibration; Chromatography, High Pressure Liquid; Dosage Forms; Fluorenes; Limit of Detection; Reproducibility of Results; Sofosbuvir; Spectrophotometry, Ultraviolet

2018
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA exper
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:11

    Topics: Adult; Antiviral Agents; Benzimidazoles; Disease Eradication; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Fluorenes; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2017
Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Sep-15, Volume: 65, Issue:6

    Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Propensity Score; Proportional Hazards Models; Ritonavir; Sofosbuvir; Sulfonamides; Survival Rate; Sustained Virologic Response; Uracil; Valine

2017
Spectroflurimetric estimation of the new antiviral agent ledipasvir in presence of sofosbuvir.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2018, Feb-05, Volume: 190

    Topics: Antiviral Agents; Benzimidazoles; Buffers; Drug Compounding; Fluorenes; Hydrogen-Ion Concentration; Limit of Detection; Sofosbuvir; Solvents; Spectrometry, Fluorescence; Time Factors

2018
Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.
    Hemodialysis international. International Symposium on Home Hemodialysis, 2018, Volume: 22, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Renal Dialysis; Sofosbuvir; Treatment Outcome; Young Adult

2018
Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 01-06, Volume: 66, Issue:2

    Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Heart Transplantation; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome; Valine; Young Adult

2018
Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:3

    Topics: Absenteeism; Antiviral Agents; Asia; Benzimidazoles; Efficiency; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome; Work Performance

2018
Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).
    Scientific reports, 2017, 10-31, Volume: 7, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Cell Line; Combined Modality Therapy; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Theoretical; Sofosbuvir; Uridine Monophosphate

2017
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2018, Volume: 16, Issue:6

    Topics: Adult; Antineoplastic Agents; Antiviral Agents; Benzimidazoles; Drug Therapy; Female; Fluorenes; Hematologic Neoplasms; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir

2018
The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Carbamates; Cell Line; Cyclosporine; Everolimus; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Pyrrolidines; Sirolimus; Sofosbuvir; Valine; Virus Replication

2018
Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load

2018
Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Aged; Aged, 80 and over; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir

2018
Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.
    Hepatology (Baltimore, Md.), 2018, Volume: 67, Issue:5

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Sofosbuvir

2018
Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:7

    Topics: Aged; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2018
Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Drug Utilization; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Valine; Young Adult

2018
Comparison between core-shell and totally porous particle stationary phases for fast and green LC determination of five hepatitis-C antiviral drugs.
    Journal of separation science, 2018, Volume: 41, Issue:8

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Imidazoles; Molecular Conformation; Particle Size; Porosity; Pyrrolidines; Simeprevir; Sofosbuvir; Surface Properties; Valine

2018
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2018, Volume: 16, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; North America; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2018
Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Directly Observed Therapy; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Medication Adherence; Middle Aged; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response; Treatment Outcome; Young Adult

2018
Chemometric simultaneous determination of Sofosbuvir and Ledipasvir in pharmaceutical dosage form.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2018, Apr-05, Volume: 194

    Topics: Benzimidazoles; Chromatography, High Pressure Liquid; Drug Compounding; Fluorenes; Least-Squares Analysis; Sofosbuvir; Spectrophotometry; Wavelet Analysis

2018
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
    Melanoma research, 2018, Volume: 28, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Humanized; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Fluorenes; Hepatitis B; Hepatitis C; Humans; Interferons; Lung Neoplasms; Male; Melanoma; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Skin Neoplasms; Sofosbuvir

2018
Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.
    Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Sequence Deletion; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins

2018
Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2018, Volume: 37, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Hepatitis C; Humans; Kidney Failure, Chronic; Renal Dialysis; Sofosbuvir

2018
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.
    Scientific reports, 2018, 02-16, Volume: 8, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prevalence; Simeprevir; Sofosbuvir

2018
No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2018, Volume: 16, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Black People; California; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Time Factors; Treatment Outcome

2018
Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    Journal of gastroenterology, 2018, Volume: 53, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Red Cross; Retrospective Studies; Risk; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins; Young Adult

2018
Direct-acting antivirals response in an acute nosocomial genotype 1b HCV outbreak.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018, Volume: 50, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cross Infection; Disease Outbreaks; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors

2018
Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load; Young Adult

2018
Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.
    AIDS research and human retroviruses, 2018, Volume: 34, Issue:8

    Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Georgia; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Sofosbuvir; Tenofovir; Young Adult

2018
Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?
    Journal of hepatology, 2018, Volume: 69, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Sofosbuvir

2018
Editorial: retreatment of DAA-failures-no problem at all?
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:11

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Retreatment; Ribavirin; Simeprevir; Sofosbuvir

2018
Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis.
    Scientific reports, 2018, 06-11, Volume: 8, Issue:1

    Topics: Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Molecular Dynamics Simulation; Mutation, Missense; Protein Conformation; Recurrence; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins

2018
Successful DAA-Based Treatment of Hcv-Related Fibrosing Cholestatic Hepatitis After Liver Transplantation Due to a Fulminant Liver Failure.
    The American journal of gastroenterology, 2018, Volume: 113, Issue:7

    Topics: Adult; Antiviral Agents; Benzimidazoles; Diagnosis, Differential; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Jaundice, Obstructive; Liver Failure, Acute; Liver Transplantation; Male; Postoperative Complications; Sofosbuvir

2018
The "real-world" efficacy and safety of DAAs for the treatment of HCV patients throughout Japan.
    Journal of gastroenterology, 2018, Volume: 53, Issue:10

    Topics: Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Japan; Red Cross; Sofosbuvir

2018
Editorial: is sofosbuvir-based therapy suitable for patients with advanced chronic kidney disease?
    Alimentary pharmacology & therapeutics, 2018, Volume: 48, Issue:3

    Topics: 2-Naphthylamine; Anilides; Benzimidazoles; Carbamates; Cyclopropanes; Fluorenes; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Renal Insufficiency, Chronic; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine

2018
Remission of chronic inflammatory demyelinating polyneuropathy after hepatitis C virus eradication with sofosbuvir and ledipasvir therapy.
    Muscle & nerve, 2018, Volume: 58, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Male; Middle Aged; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Recurrence; Sofosbuvir

2018
Earth-friendly spectrophotometric methods for simultaneous determination of ledipasvir and sofosbuvir: Application to average content and uniformity of dosage unit testing.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2018, Dec-05, Volume: 205

    Topics: Benzimidazoles; Fluorenes; Green Chemistry Technology; Limit of Detection; Linear Models; Reproducibility of Results; Sofosbuvir; Spectrophotometry; Tablets; Uridine Monophosphate

2018
Development of a highly sensitive high-performance thin-layer chromatography method for the screening and simultaneous determination of sofosbuvir, daclatasvir, and ledipasvir in their pure forms and their different pharmaceutical formulations.
    Journal of separation science, 2018, Volume: 41, Issue:18

    Topics: Benzimidazoles; Carbamates; Chromatography, Thin Layer; Drug Compounding; Fluorenes; Imidazoles; Pyrrolidines; Sofosbuvir; Valine

2018
High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2018, Volume: 75

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Community Health Centers; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response

2018
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
    Indian journal of pediatrics, 2019, Volume: 86, Issue:2

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Carbamates; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load

2019
Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Renal Insufficiency; Sofosbuvir; Treatment Outcome; Valine; Viral Nonstructural Proteins; Young Adult

2018
Potential Overestimation of Racial Disparities in Response to the 8-Week Ledipasvir/Sofosbuvir Regimen for Hepatitis C Virus Genotype 1 Infection.
    Gastroenterology, 2018, Volume: 155, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Health Status Disparities; Hepacivirus; Hepatitis C; Humans; Sofosbuvir

2018
Findings from a large Asian chronic hepatitis C real-life study.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:12

    Topics: Adult; Antiviral Agents; Asia; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Acute changes in cardiac function by direct acting antiviral therapy for hepatitis C-infected patients with thalassemia.
    Journal of medical virology, 2019, Volume: 91, Issue:3

    Topics: Adolescent; Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Heart; Heart Diseases; Heart Function Tests; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Thalassemia; Young Adult

2019
No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C; Humans; RNA; Sofosbuvir

2018
The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.
    Antiviral therapy, 2018, Volume: 23, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Sofosbuvir; Viremia; Virus Activation

2018
Using telehealth to improve access to hepatitis C treatment in the direct-acting antiviral therapy era.
    Journal of telemedicine and telecare, 2020, Volume: 26, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Delivery of Health Care; Female; Fluorenes; Health Services Accessibility; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Telemedicine; Treatment Outcome; Valine

2020
Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir.
    World journal of gastroenterology, 2018, Oct-28, Volume: 24, Issue:40

    Topics: Adult; Antiviral Agents; Benzimidazoles; Case-Control Studies; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Killer Cells, Natural; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response

2018
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.
    The American journal of gastroenterology, 2019, Volume: 114, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Breast Neoplasms; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Head and Neck Neoplasms; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferons; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2019
Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus.
    Clinical journal of gastroenterology, 2019, Volume: 12, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; RNA; Sofosbuvir; Sulfonamides; Valine

2019
Simultaneous quantification of simeprevir sodium: A hepatitis C protease inhibitor in binary and ternary mixtures with sofosbuvir and/or ledipasvir utilizing direct and H-point standard addition strategies.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2019, Mar-05, Volume: 210

    Topics: Antiviral Agents; Artifacts; Benzimidazoles; Calibration; Complex Mixtures; Fluorenes; Hepacivirus; Protease Inhibitors; Reproducibility of Results; Simeprevir; Sofosbuvir; Spectrophotometry, Ultraviolet

2019
Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.
    Canadian journal of gastroenterology & hepatology, 2018, Volume: 2018

    Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; China; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine; Viral Nonstructural Proteins

2018
Direct-acting antiviral therapy in sub-Saharan Africa.
    The lancet. Gastroenterology & hepatology, 2019, Volume: 4, Issue:2

    Topics: Africa South of the Sahara; Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Rwanda; Sofosbuvir

2019
Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
    Hepatology international, 2019, Volume: 13, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response

2019
Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissoluti
    Drug development and industrial pharmacy, 2019, Volume: 45, Issue:7

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Imidazoles; Limit of Detection; Pyrrolidines; Reproducibility of Results; Ribavirin; Sensitivity and Specificity; Sofosbuvir; Solubility; Valine

2019
Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4.
    Cells, 2019, 05-05, Volume: 8, Issue:5

    Topics: Adolescent; Benzimidazoles; Child; Drug Resistance, Viral; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Phylogeny; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins

2019
Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.
    The Journal of antimicrobial chemotherapy, 2019, 08-01, Volume: 74, Issue:8

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Benzimidazoles; Blood Chemical Analysis; Chromatography, Liquid; Drug Interactions; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Phosphorous Acids; Sofosbuvir; Tandem Mass Spectrometry; Tenofovir; Young Adult

2019
Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.
    Zeitschrift fur Gastroenterologie, 2019, Volume: 57, Issue:5

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Prospective Studies; Registries; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2019
Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks.
    The Journal of infection, 2019, Volume: 79, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2019
Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients.
    Clinical and experimental medicine, 2019, Volume: 19, Issue:3

    Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Immunity, Innate; Killer Cells, Natural; Longitudinal Studies; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 1; NK Cell Lectin-Like Receptor Subfamily C; Sofosbuvir; Time Factors; Young Adult

2019
Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C.
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2019, Volume: 32, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Recurrence; Regression Analysis; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Failure

2019
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Safety; Sofosbuvir; Taiwan; Treatment Outcome

2020
Flecainide plasma level modifications during ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C.
    Antiviral therapy, 2019, Volume: 24, Issue:7

    Topics: Aged; Anti-Arrhythmia Agents; Antiviral Agents; Arrhythmias, Cardiac; Benzimidazoles; Drug Interactions; Drug Therapy, Combination; Flecainide; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir

2019
Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
    Current drug safety, 2020, Volume: 15, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Random Allocation; Sofosbuvir; Treatment Outcome; Valine

2020
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
    Journal of medical virology, 2020, Volume: 92, Issue:2

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Mutation; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Valine

2020
Chemometrically Assisted Development of Ultra-High-Performance Liquid Chromatography Method for the Simultaneous Quantification of Sofosbuvir, Daclatasvir and Ledipasvir in Pharmaceutical Dosage Forms.
    Journal of chromatographic science, 2020, Jan-17, Volume: 57, Issue:10

    Topics: Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Sofosbuvir; Tablets; Valine

2020
Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2020, Volume: 119, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mongolia; Sofosbuvir; Treatment Failure; Treatment Outcome; Uridine Monophosphate

2020
[QOL Assessment in Chronic Hepatitis C Patients Receiving Ledipasvir/ Sofosbuvir or Simeprevir/Peginterferon/Ribavirin in Clinical Practice].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2019, Volume: 139, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Surveys and Questionnaires

2019
High risk of hepatitis B virus reactivation among patients treated with direct-acting antivirals and coinfected with HCV and HIV.
    The Journal of infection, 2020, Volume: 80, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Fluorenes; Hepatitis B virus; Hepatitis C, Chronic; HIV Infections; Humans; Recurrence; Sofosbuvir

2020
Micellar-based spectrofluorimetric method for the selective determination of ledipasvir in the presence of sofosbuvir: application to dosage forms and human plasma.
    Luminescence : the journal of biological and chemical luminescence, 2020, Volume: 35, Issue:4

    Topics: Benzimidazoles; Drug Compounding; Fluorenes; Humans; Micelles; Molecular Structure; Sofosbuvir; Spectrometry, Fluorescence; Tablets

2020
Hepatitis C virus therapy in children: No one should be left behind.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:2

    Topics: Benzimidazoles; Child; Child, Preschool; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir

2020
Hepatitis C Virus-associated Lymphoplasmacytic Lymphoma With Waldenström Macroglobulinemia: Response to Direct-acting Antiviral Therapy.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:4

    Topics: Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sofosbuvir; Waldenstrom Macroglobulinemia

2020
A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program.
    PloS one, 2020, Volume: 15, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Odds Ratio; Primary Health Care; Program Evaluation; Reward; Safety-net Providers; Sofosbuvir; Sustained Virologic Response; Young Adult

2020
Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness.
    Journal of the Pediatric Infectious Diseases Society, 2021, Feb-13, Volume: 10, Issue:1

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Fluorenes; Hematologic Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Male; Sofosbuvir; Treatment Outcome

2021
Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease.
    Blood purification, 2020, Volume: 49, Issue:6

    Topics: Adult; Aged; Benzimidazoles; Carbamates; Clinical Trials as Topic; Drug Monitoring; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Sofosbuvir; Treatment Outcome; Valine

2020
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:9

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan

2020
Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 06-02, Volume: 117, Issue:22

    Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Imidazoles; Liver Cirrhosis; Models, Animal; Pyrrolidines; Ribavirin; Sofosbuvir; Swine; Valine

2020
Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection.
    The American journal of case reports, 2020, Jun-04, Volume: 21

    Topics: Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Sofosbuvir; Sustained Virologic Response

2020
HCV eradication in chronic kidney disease: ready for prime time?
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:10

    Topics: Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir

2020
Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience.
    Transplantation proceedings, 2020, Volume: 52, Issue:10

    Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; France; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2020
Acute Renal Failure in a Patient on Ledipasvir-Sofosbuvir Therapy for Hepatitis C.
    American journal of therapeutics, 2020, 07-31, Volume: 28, Issue:6

    Topics: Acute Kidney Injury; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome

2020
Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.
    The Journal of antimicrobial chemotherapy, 2020, 11-01, Volume: 75, Issue:11

    Topics: Adenine; Alanine; Anti-HIV Agents; Benzimidazoles; Fluorenes; HIV Infections; Humans; Protease Inhibitors; Sofosbuvir; Tenofovir

2020
Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan.
    Journal of viral hepatitis, 2021, Volume: 28, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Neoplasms; Sofosbuvir; Sustained Virologic Response

2021
Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2021, Volume: 120, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Taiwan; Treatment Outcome

2021
Treatment of chronic hepatitis C virus infection with crushed ledipasvir/sofosbuvir administered through a percutaneous endoscopic gastrostomy tube in a patient with HIV coinfection.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2021, 01-01, Volume: 78, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Gastrostomy; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir; Treatment Outcome

2021
Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms.
    Molecules (Basel, Switzerland), 2020, Oct-10, Volume: 25, Issue:20

    Topics: Antiviral Agents; Benzimidazoles; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Fluorenes; Hepatitis C, Chronic; Limit of Detection; Simeprevir; Sofosbuvir; Temperature

2020
Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study.
    The New Zealand medical journal, 2020, 11-20, Volume: 133, Issue:1525

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Seropositivity; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; New Zealand; Pyrrolidines; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load

2020
Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study.
    Clinical and molecular hepatology, 2021, Volume: 27, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Mongolia; Sofosbuvir; Treatment Outcome

2021
Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care.
    Clinical and molecular hepatology, 2021, Volume: 27, Issue:1

    Topics: Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Humans; Sofosbuvir

2021
Rapid and sensitive UHPLC-DAD method for simultaneous determination of sofosbuvir and ledipasvir in human serum.
    Journal of pharmaceutical and biomedical analysis, 2021, Feb-20, Volume: 195

    Topics: Antiviral Agents; Benzimidazoles; Chromatography, High Pressure Liquid; Fluorenes; Hepatitis C, Chronic; Humans; Reproducibility of Results; Sofosbuvir

2021
Sofosbuvir/Ledipasvir for Treatment of Chronic Hepatitis C Infection in Adult Patients with β- Thalassemia Major: A Real-Life Study.
    Endocrine, metabolic & immune disorders drug targets, 2022, Volume: 22, Issue:3

    Topics: Adult; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Retrospective Studies; Sofosbuvir; Thalassemia; Treatment Outcome; Uridine Monophosphate

2022
Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals.
    The Journal of pediatrics, 2021, Volume: 233

    Topics: Adolescent; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Child; Elasticity Imaging Techniques; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Prospective Studies; Sofosbuvir

2021
Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis.
    Internal medicine (Tokyo, Japan), 2021, Volume: 60, Issue:5

    Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Muscle, Skeletal; Quality of Life; Sofosbuvir; Treatment Outcome

2021
Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa.
    The Journal of infectious diseases, 2022, 09-21, Volume: 226, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Retreatment; Sofosbuvir; Sustained Virologic Response

2022
Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient.
    Journal of clinical immunology, 2021, Volume: 41, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Child; Female; Fluorenes; Gain of Function Mutation; Genotype; Hepatitis C; Humans; Sofosbuvir; STAT3 Transcription Factor

2021
Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 107

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Developing Countries; Drug Interactions; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Treatment Outcome; Young Adult

2021
Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.
    BMC infectious diseases, 2021, Apr-26, Volume: 21, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2021
Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2021, Volume: 32, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Turkey

2021
Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients.
    Clinics and research in hepatology and gastroenterology, 2021, Volume: 45, Issue:5

    Topics: Adolescent; Adult; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2021
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease.
    The American journal of gastroenterology, 2021, 09-01, Volume: 116, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C; Humans; Kidney Failure, Chronic; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
    European journal of gastroenterology & hepatology, 2021, 12-01, Volume: 33, Issue:1S Suppl 1

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2021
Factors associated with a reduction in the quality of life of patients with chronic hepatitis C treated by ledipasvir/sofosbuvir therapy.
    European journal of hospital pharmacy : science and practice, 2021, Volume: 28, Issue:Suppl 2

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Quality of Life; Sofosbuvir

2021
Innovative derivative/zero ratio spectrophotometric method for simultaneous determination of sofosbuvir and ledipasvir: Application to average content and uniformity of dosage units.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2022, Feb-15, Volume: 267, Issue:Pt 2

    Topics: Benzimidazoles; COVID-19; Fluorenes; Humans; Reproducibility of Results; SARS-CoV-2; Sofosbuvir; Spectrophotometry

2022
Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 08-31, Volume: 75, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; DNA, Viral; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Taiwan

2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:8

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Registries; Ribavirin; Sofosbuvir; Taiwan; Uridine Monophosphate

2022
Assessment of outcome for sample of Iraqi patients with chronic hepatitis C virus infection treated by Ledipasvir/sofosbuvir drug.
    JPMA. The Journal of the Pakistan Medical Association, 2021, Volume: 71(Suppl 8), Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2021
The Influence of Treatment with Ledipasvir/Sofosbuvir on Growth Parameters in Children and Adolescents with Chronic Hepatitis C.
    Viruses, 2022, 02-25, Volume: 14, Issue:3

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Sofosbuvir; Treatment Outcome

2022
Real-Life Data on Sofosbuvir/Ledipasvir in Patients with Chronic Viral Hepatitis C Genotype 1b: A Single-Center Experience.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2022, Volume: 33, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2022
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.
    The Korean journal of internal medicine, 2022, Volume: 37, Issue:6

    Topics: Antiviral Agents; Cohort Studies; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Republic of Korea; RNA; Sofosbuvir; Treatment Outcome

2022
In-depth investigation of the Silymarin effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 and ledipasvir in rat plasma using LC-MS.
    Biomedical chromatography : BMC, 2022, Volume: 36, Issue:9

    Topics: Animals; Antiviral Agents; Benzimidazoles; Chromatography, Liquid; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Male; Rats; Silymarin; Sofosbuvir; Tandem Mass Spectrometry

2022
Safety and Efficacy of Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C Virus Infection in Treatment-Naïve Children without and with Comorbidities.
    Paediatric drugs, 2022, Volume: 24, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Quality of Life; Sofosbuvir; Treatment Outcome

2022
Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.
    Internal medicine (Tokyo, Japan), 2023, Sep-01, Volume: 62, Issue:17

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir

2023
Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.
    PloS one, 2023, Volume: 18, Issue:1

    Topics: Drug Costs; Health Expenditures; Hepatitis C; Humans; Medication Adherence; Retrospective Studies; Sofosbuvir

2023
Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.
    Digestive diseases and sciences, 2023, Volume: 68, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Porphyria Cutanea Tarda; Porphyrins; RNA; Sofosbuvir; Treatment Outcome

2023
Non-ANCA Leucocytoclasic Vasculitis Induced by Sofosbuvir/Ledipasvir Treatment: A Case Report.
    Current drug safety, 2024, Volume: 19, Issue:1

    Topics: Antibodies, Antineutrophil Cytoplasmic; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Sofosbuvir; Treatment Outcome; Vasculitis

2024
Human pegivirus viremia in HCV/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2023, Volume: 162

    Topics: Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferons; Male; Pegivirus; Polyethylene Glycols; RNA, Viral; Sofosbuvir; Viremia

2023